Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 15323. Отображено 100.
19-01-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer

Номер: US20120016019A1
Автор: Gee-Hwoon LEE
Принадлежит: Individual

The present invention relates to a compound of the formula I: wherein R is C 2 H 5 or C 2 H 3 , or a pharmaceutically acceptable salt or hydrate thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, for treating or preventing cancers.

Подробнее
16-02-2012 дата публикации

Substituted acylguanidine derivatives (as amended)

Номер: US20120041036A1
Принадлежит: Astellas Pharma Inc

An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT 5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT 5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
22-03-2012 дата публикации

Metallo-beta-lactamase inhibitors

Номер: US20120071457A1
Принадлежит: Individual

A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

Подробнее
29-03-2012 дата публикации

Method For Improved Bioactivation Of Pharmaceuticals

Номер: US20120077876A1

This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R 1 and R 2 are hydrogen, alkyl, or aryl radicals.

Подробнее
14-06-2012 дата публикации

Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Номер: US20120149637A1
Принадлежит: Individual

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Подробнее
05-07-2012 дата публикации

Zinc cluster

Номер: US20120172601A1
Принадлежит: Takasago International Corp

Disclosed is a novel zinc cluster compound represented by general formula (1): Zn 4 O (OCOR) 6 (RCOOH) n , wherein R represents an alkyl group which has 1 to 4 carbon atoms and may be substituted with a halogen atom, and n represents 0.1 to 1, and also disclosed are a method for producing the compound and a reaction using the compound.

Подробнее
26-07-2012 дата публикации

Methods and compositions for heavy metal detoxification

Номер: US20120189721A1
Принадлежит: Metaproteomics Llc

Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.

Подробнее
09-08-2012 дата публикации

Substituted 4-aminocyclohexane derivatives

Номер: US20120202810A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Подробнее
09-08-2012 дата публикации

Anti-influenza agents

Номер: US20120202877A1
Принадлежит: Griffith University

The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
30-08-2012 дата публикации

2-phenylethylamino derivatives as calcium and/or sodium channel modulators

Номер: US20120220592A1
Принадлежит: Newron Pharmaceuticals SpA

2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.

Подробнее
06-09-2012 дата публикации

Compositions and methods useful for treating diseases

Номер: US20120225851A1
Принадлежит: Eutropics Pharmaceuticals Inc

The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia′, Ib′, Ic′, or II′. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

Подробнее
25-10-2012 дата публикации

Sialochimeric compounds

Номер: US20120269771A1
Принадлежит: Therapicon Srl

The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.

Подробнее
08-11-2012 дата публикации

Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof

Номер: US20120282180A1
Принадлежит: Siemens Medical Solutions USA Inc

The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the inhibitors of matrix-metalloproteinases (MMPs) of the invention and of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention.

Подробнее
29-11-2012 дата публикации

Process of making alpha-aminooxyketone/alpha-aminooxyaldehyde and alpha-hydroxyketone/alpha-hydroxyaldehyde compounds and a process making reaction products from cyclic alpha, beta-unsaturated ketone substrates and nitroso substrates

Номер: US20120302792A1
Принадлежит: JAPAN SCIENCE AND TECHNOLOGY AGENCY

The present invention is directed to a process of making α-aminooxyketone and α-hydroxyketone compounds. The synthetic pathway generally involves reacting an aldehyde or ketone substrate and a nitroso substrate in the presence of a catalyst of the formula (IV): wherein X a -X c represent independently nitrogen, carbon, oxygen or sulfur and Z represents a 4 to 10-membered ring with or without a substituent and optionally a further step to convert the α-aminooxyketone compound formed to the α-hydroxyketone compound. The present invention results in α-aminooxyketone and α-hydroxyketone compounds with high enantioselectivity and high purity. The present invention is also directed to a catalytic asymmetric O-nitroso Aldol/Michael reaction. The substrates of this reaction are generally cyclic α,β-unsaturated ketone substrate and a nitroso substrate. This methodology generally involves reacting the cyclic α,β-unsaturated ketone substrate and the nitroso substrate in the presence of a proline-based catalyst, to provide a heterocyclic product.

Подробнее
06-12-2012 дата публикации

Compounds and methods for treating bacterial infections

Номер: US20120309701A1
Принадлежит: Washington University in St Louis WUSTL

The present invention encompasses compounds and methods for treating urinary tract infections.

Подробнее
20-12-2012 дата публикации

Process and intermediate compounds useful in the preparation of statins

Номер: US20120323011A1
Принадлежит: Redx Pharna PLC

There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein R a represents an alkyl group, such as a C 1-16 alkyl group, and preferably an isopropyl group; R b represents an aryl group, preferably a 4-fluorophenyl group; R c represents hydrogen, a protecting group or an alkyl group, such as a C 1-16 alkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SO 2 R e group where R e is an alkyl group, such as a C 1-16 alkyl group, and preferably a methyl group.

Подробнее
31-01-2013 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20130028859A1
Принадлежит: Bristol Myers Squibb Co

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Подробнее
21-02-2013 дата публикации

Production and use of antibacterial, antiproliferative, and antiphytopathogenic benzanthracenes

Номер: US20130045931A1

The invention relates to a compound of the general structure (I), where R is a hydrogen atom (H) or an unsubstituted, monosubstituted, or polysubstituted C 1 -C 20 alkyl, wherein the alkyl can be straight, branched, cyclic, or partially unsaturated, or an unsubstituted, monosubstituted, or polysubstituted phenyl group.

Подробнее
25-04-2013 дата публикации

Cyclohexylamines

Номер: US20130101667A1
Принадлежит: Endo Pharmaceuticals Inc

The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.

Подробнее
09-05-2013 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20130115193A1
Принадлежит: Bristol Myers Squibb Co

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Подробнее
16-05-2013 дата публикации

Synthesis of High Caloric Fuels and Chemicals

Номер: US20130118063A1
Принадлежит: PIONEER ENERGY INC

In one embodiment, the present application discloses methods to selectively synthesize higher alcohols and hydrocarbons useful as fuels and industrial chemicals from syngas and biomass. Ketene and ketonization chemistry along with hydrogenation reactions are used to synthesize fuels and chemicals. In another embodiment, ketene used to form fuels and chemicals may be manufactured from acetic acid which in turn can be synthesized from synthesis gas which is produced from coal, biomass, natural gas, etc.

Подробнее
06-06-2013 дата публикации

Guanidine compound

Номер: US20130143860A1
Принадлежит: Astellas Pharma Inc

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Подробнее
13-06-2013 дата публикации

THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS

Номер: US20130150390A1
Автор: Kaino Mie, Meguro Hiroyuki
Принадлежит:

A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect. 16-. (canceled)8. The therapeutic or prophylactic agent of claim 7 , wherein in said Formula (I) claim 7 ,V is —CH═CH—, andwhen Y is represented by the Formula (II), m is 0; orwhen Y is represented by the Formula (III), p is 1.9. The therapeutic or prophylactic agent of claim 8 , wherein in Formula (I) claim 8 ,{'sup': '1', 'Ris hydrogen; and'}{'sup': 4', '4, 'sub': 1', '3, 'when Y is represented by the Formula (II), W is —N(R)— and Ris C-Calkyl, cyanoethyl, tetrahydropyranyl or phenyl; or'}{'sup': '3', 'sub': 1', '3, 'when Y is represented by the Formula (III), n is 0 and Ris C-Calkyl.'}11. A method of producing a therapeutic or prophylactic agent for allergic dermatitis comprising using the compound of the Formula (I) or the pharmaceutically acceptable salt thereof recited for the production of the therapeutic or prophylactic agent for allergic dermatitis.13. A method of producing a therapeutic or prophylactic agent for allergic dermatitis comprising using the compound of the Formula (I) or the pharmaceutically acceptable salt thereof recited for the production of the therapeutic or prophylactic agent for allergic dermatitis.14. The therapeutic method for allergic dermatitis of claim 12 , wherein claim 12 , in said Formula (I) claim 12 ,V is —CH═CH—, andwhen Y is represented by the Formula (II), m is 0; orwhen Y is represented by the Formula (III), p is 1.15. A method of producing a therapeutic or prophylactic agent for allergic dermatitis comprising ...

Подробнее
27-06-2013 дата публикации

TETRASUBSTITUTED BENZENES

Номер: US20130165486A1
Принадлежит: EnVivo Pharmaceuticals, Inc.

Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described. 162.-. (canceled)64. The compound of claim 63 , wherein Rand Rare independently selected from the group consisting of (a) H claim 63 , (b) (C-C)alkyl and (c) (C-C)alkyl-(C-C)cycloalkyl provided that both Rand Rare not H claim 63 , wherein each alkyl or cycloalkyl of Rand Ris optionally independently substituted with one or more groups selected from the group consisting of halo claim 63 , hydroxy claim 63 , cyano claim 63 , CFand (C-C)alkyl claim 63 ,or{'sub': 1', '2', '1', '4', '3', '1', '4, 'Rand Rtaken together with the carbon to which they are attached form a 3-7 membered cycloalkyl or heterocycloalkyl ring which optionally bears a C-Calkyl substituent that can be optionally independently substituted with one or more groups selected from the group consisting of halo, hydroxy, oxo, cyano, CFand (C-C)alkyl,'}or{'sub': 1', '2', '20', '21', '20', '21', '3', '1', '4, 'Rand Rare taken together with the carbon to which they are attached form a 3-7 membered cycloalkyl ring substituted with Rand Rwherein Rand Rtaken together with the carbon or carbons to which they are attached form a 3-7 membered cycloalkyl ring wherein each cycloalkyl is optionally independently substituted with one or more groups selected from the group consisting of halo, hydroxy, cyano, CFand (C-C)alkyl;'}Y is —O—,{'sub': '4', 'claim-text': [{'sub': 0', '3', '3', '7, '(a) (C-C)alkyl(C-C)cycloalkyl,'}, '(b) trifluoroethyl and', '(c) trifluoropropyl;', {'sub': 6', '3', '2', '1', '4', '2', '2', '3', '6', '6', '2', '6, 'Z is a phenyl ring optionally bearing up to 3 substituents independently selected from the group consisting of halogen, R, CF, CN, NO, OH, (C-C)alkoxy, OCHCHOCH, SR, S(O)Rand S(O)R;'}], 'Ris selected from the group consisting of'}{'sub': 5', '3, 'claim-text': [{'sub': '6', 'Ris selected ...

Подробнее
27-06-2013 дата публикации

RUTHENIUM COMPLEXES FOR USE IN OLEFIN METATHESIS

Номер: US20130165649A1
Автор: Cazin Catherine
Принадлежит:

Cls ruthenium complexes that can be used as catalysts are described. The complexes are generally square pyramidal in nature, having two anionic ligands X adjacent to each other. The complexes can be used as catalysts, for example in olefin metathesis reactions. Corresponding trans ruthenium complexes are also described, together with cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand. 2. The cis ruthenium complex according to wherein the anionic ligands X are independently selected from the group consisting of halogen claim 1 , benzoate claim 1 , C-Ccarboxylates claim 1 , C-Calkoxy claim 1 , phenoxy claim 1 , C-Calkyl thio groups claim 1 , tosylate claim 1 , mesylate claim 1 , brosylate claim 1 , trifluoromethane sulfonate claim 1 , and pseudo-halogens.3. The cis ruthenium complex according to wherein the groups Rand Rare H and aryl.4. The cis ruthenium complex according to wherein the groups Rand Rare fused to form a substituted or unsubstituted indenylidene moiety.6. The cis ruthenium complex according to wherein the phosphite group is selected from the group consisting of P(OMe)P(OEt) claim 5 , P(OiPr)and P(OPh).7. The cis ruthenium complex according to wherein the group A is a nucleophilic carbene having a four claim 1 , five claim 1 , six or seven membered ring containing the carbene carbon.8. The cis ruthenium complex according to wherein the group A is an N-heterocyclic carbene.9. The cis ruthenium complex according to wherein the N-heterocyclic carbene ligand contains more than one nitrogen atom in the ring and/or contains at least one of O or S in the ring.11. The cis ruthenium complex according to wherein the N-heterocyclic carbene ligand contains two nitrogen atoms in the ring claim 9 , each adjacent the carbene carbon.18. The method of wherein the leaving group L is selected from the group cnsisting of; substituted or unsubstituted pyridine claim 17 , phosphine claim 17 , phosphite claim 17 , ...

Подробнее
04-07-2013 дата публикации

DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE

Номер: US20130171180A1
Принадлежит: TFCHEM

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, as well as to their process of preparation, their use in the peptide synthesis, said peptide and the use of said peptide. 121.-. (canceled)24. The compound according to claim 22 , wherein R represents a CHORgroup; Rand Rrepresent claim 22 , independently from one another claim 22 , an ORgroup; and Rrepresents an ORor NRC(O)Rgroup.25. The compound according to claim 22 , wherein Rrepresents a hydrogen atom or an ORgroup.26. The compound according to claim 22 , wherein Y represents a NRRor CHNRRgroup.27. The compound according to claim 22 , wherein Rrepresents an ORgroup.28. The compound according to claim 22 , wherein Y represents a NRRor CHNRRgroup and Rrepresents an ORgroup claim 22 , with:{'sub': 6', '7', '49, 'Rand Rrepresenting each a hydrogen atom and Rrepresenting an O-protecting group, or'}{'sub': 49', '6', '7, 'Rand Rrepresenting each a hydrogen atom and Rrepresenting a N-protecting group.'}32. A peptide (VI) wherein at least one amino acid has been replaced with a compound of formula (I) according to wherein Y═NHRor CHNHRand/or R═OH claim 22 , the Y and/or Rgroup being linked to an amino acid of the peptide by a peptide bond.34. A pharmaceutical or cosmetic composition comprising at least one peptide (VI) according to and a pharmaceutically acceptable carrier.35. The compound according to claim 24 , wherein R claim 24 , Rand Rrepresent a hydrogen atom or an O-protecting group claim 24 , Rrepresents a hydrogen atom and Rrepresents a (C-C)alkyl group.36. The compound according to claim 25 , wherein Rrepresents a hydrogen atom or an O-protecting group37. The compound according to claim 26 , wherein Rrepresents a hydrogen atom or a (C-C)alkyl group and Rrepresents:a hydrogen atom,{'sub': 1', '6', '1', '6, ' ...

Подробнее
04-07-2013 дата публикации

PROCESS FOR PREPARING 1, 6-HEXANEDIOL

Номер: US20130172578A1
Принадлежит: E I DU PONT DE NEMOURS AND COMPANY

Disclosed are processes for preparing 1,6-hexanediol and synthetic intermediates useful in the production of 1,6-hexanediol from renewable biosources. In one embodiment, a process comprises contacting levoglucosenone with hydrogen in the presence of a first hydrogenation catalyst at a first temperature to form product mixture (I); and heating product mixture (I) in the presence of hydrogen and a second hydrogenation catalyst at a second temperature to form product mixture (II) which comprises 1,6-hexanediol. 1. A process comprising:a) contacting levoglucosenone with hydrogen in the presence of a first hydrogenation catalyst at a first temperature between about 25° C. and about 150° C. to form product mixture (I); andb) heating product mixture (I) in the presence of hydrogen and a second hydrogenation catalyst at a second temperature between about 120° C. and about 260° C. to form product mixture (II).2. The process of claim 1 , wherein product mixture (I) comprises one or more of levoglucosenol claim 1 , levoglucosanol claim 1 , tetrahydrofuran 2 claim 1 ,5-dimethanol claim 1 , 2-hydroxymethyltetrahydropyran claim 1 , 1 claim 1 ,2 claim 1 ,5 claim 1 ,6-tetrahydroxyhexane claim 1 , 1 claim 1 ,2 claim 1 ,6-hexanetriol claim 1 , and 2-hydroxymethyl-5-hydroxytetrahydropyran.3. The process of claim 1 , wherein product mixture (II) comprises one or more of 1 claim 1 ,2 claim 1 ,6-hexanetriol claim 1 , tetrahydrofuran 2 claim 1 ,5-dimethanol claim 1 , 2-hydroxymethyl-5-hydroxytetrahydropyran claim 1 , 1 claim 1 ,6-hexanediol claim 1 , 1 claim 1 ,2-hexanediol claim 1 , 1-hexanol claim 1 , and 2-hydroxymethyltetrahydropyran.4. The process of claim 3 , wherein product mixture (II) comprises 1 claim 3 ,6-hexanediol.5. The process of claim 1 , wherein the first hydrogenation catalyst comprises one or more of supported platinum catalysts claim 1 , supported palladium catalysts claim 1 , supported ruthenium catalysts claim 1 , supported nickel catalysts claim 1 , catalysts ...

Подробнее
04-07-2013 дата публикации

Process for the production of hexanediols

Номер: US20130172579A1
Принадлежит: EI Du Pont de Nemours and Co

Disclosed are processes for preparing 1,2-cyclohexanediol, and mixtures of 1,2-cyclohexanediol and 1,6-hexanediol, by hydrogenating 1,2,6-hexanetriol.

Подробнее
04-07-2013 дата публикации

PRODUCTION OF HYDROXYMETHYLFURFURAL FROM LEVOGLUCOSENONE

Номер: US20130172580A1
Принадлежит: E I DU PONT DE NEMOURS AND COMPANY

Disclosed are processes comprising contacting an aqueous reaction mixture having an initial pH between about 3 and about 6 and comprising levoglucosenone with a catalyst, and heating the reaction mixture to form a product mixture comprising 5-hydroxymethyl-2-furfural. The processes may further comprise heating the product mixture comprising 5-hydroxymethyl-2-furfural in the presence of hydrogen and a hydrogenation catalyst to form a second product mixture comprising one or more of 2,5-furandimethanol, tetrahydrofuran 2,5-dimethanol, 1,2,6-hexanetriol, 2-hydroxymethyltetrahydropyran, and 1,6-hexanediol. 1. A process comprising:a) contacting an aqueous reaction mixture comprising levoglucosenone with a catalyst, wherein the initial pH of the reaction mixture is between about 3 and about 6, andb) heating the reaction mixture at a temperature between about 120° C. and about 200° C. at a pressure of ambient pressure to about 1000 psi for a time sufficient to form a product mixture comprising 5-hydroxymethyl-2-furfural.2. The process of claim 1 , wherein the concentration of levoglucosenone is between about 1 wt % and about 50 wt %.3. The process of claim 1 , wherein the temperature is between about 120° C. and about 150° C.4. The process of claim 1 , wherein the pH is between about 3 and about 4.5. The process of claim 1 , wherein the catalyst is an acid catalyst.6. The process of claim 1 , wherein the catalyst is selected from the group consisting of glycolic acid claim 1 , levulinic acid claim 1 , benzoic acid claim 1 , tungstic acid claim 1 , and phosphotungstic acid hydrate.7. The process of claim 1 , wherein the catalyst is selected from the group consisting of sulfonic acid cation exchange resins claim 1 , zeolite Y claim 1 , montmorillonite claim 1 , H-mordenite claim 1 , and tungsten oxide.8. The process of claim 1 , wherein the catalyst comprises sulfonic acid cation exchange resins claim 1 , zeolite Y claim 1 , or phosphotungstic acid claim 1 , the pH is ...

Подробнее
11-07-2013 дата публикации

Cannabinoid receptor modulators

Номер: US20130178457A1
Принадлежит: Lupin Ltd

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).

Подробнее
18-07-2013 дата публикации

N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES

Номер: US20130184279A1
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY

Compounds of formula Ia and Ib 2. The compound of claim 1 , wherein A is:{'sub': 1', '6', '40', '46', '1', '6', '29', '30', '40', '40', '40', '40', '40', '40', '1', '6, "(a) phenyl, which is substituted with one or more substituents selected from the group consisting of: 1) halo, 2) (C-C)-alkyl, which may be optionally substituted with one or more R's, 3) —OR, 4) (C-C)-alkylthio, 5) cyano, 6) nitro, 7) —NRR, 8) aryl, which may be optionally substituted with one or more R's, 9) arylalkyl, which may be optionally substituted with one or more R's, 10) heteroaryl, which may be optionally substituted with one or more R's, 11) heteroarylalkyl, which may be optionally substituted with one or more R's, 12) heterocyclyl, which may be optionally substituted with one or more R's, 13) heterocyclylalkyl, which may be optionally substituted with one or more R's, 14) halo(C-C)alkyl,"}{'sub': 46', 'p', '46', '2', '46', '46, '15) —COR, 16) ═O, 17) —S(O)R, 18) —SONHR, 19) —COOR,'}{'sub': 46', '46', '46', '2', '6', '40', '2', '6', '40', '46', '46', '46', '46', '40, "20) —NHC(CN)NHR, 21) —CONRR, 22) (C-C)-alkynyl, which may be optionally substituted with one or more R's, 23) (C-C)-alkenyl, which may be optionally substituted with one or more R's, 24) —OCOR, 25) —OCOOR, or 26) —OCONRR; or any two adjacent substituents may join together to form a 4- to 8-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with one or more R's;"}{'sub': 1', '6', '40', '46', '1', '6', '29', '30', '40', '40', '40', '40', '40', '40', '1', '6, "(b) heteroaryl, which is substituted with one or more substituents selected from the group consisting of: 1) halo, 2) (C-C)-alkyl, which may be optionally substituted with one or more R's, 3) —OR, 4) (C-C)-alkylthio, 5) cyano, 6) nitro, 7) —NRR, 8) aryl, which may be optionally substituted with one or more R's, 9) arylalkyl, which may be optionally substituted with one or more R's, 10) heteroaryl, which ...

Подробнее
18-07-2013 дата публикации

Processes for Making Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130184292A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.

Подробнее
25-07-2013 дата публикации

Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)

Номер: US20130190399A1
Принадлежит: Martek Biosciences Corporation

The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC-PUFAs, C28-C42:4, 5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor. 1. A method of coupling a long chain hydrocarbon to an extender hydrocarbon to form a very long chain hydrocarbon having at last 28 carbon atoms comprising:i. reacting a long chain hydrocarbon, having a nucleophillic displacement group on one end, with an extending reagent,ii. wherein the extending reagent comprises a nucleophillic attacking group and an extender hydrocarbon chain having a protecting functional group on one end, andiii. wherein the coupling is done in the presence of an activating catalyst.2. The method as recited in wherein the protecting functional group is selected from an ester and an ether.3. The method as recited in where the nucleophillic displacement group is a halogen.4. The method as recited in wherein the extending reagent is selected from a Grignard extender reagent and a zinc extender reagent.538-. (canceled)39. A method of lengthening a polyunsaturated fatty acid to form an ester comprising:a. reducing an ester of a first polyunsaturated fatty acid to form a primary alcohol;b. oxidizing the primary alcohol to form an aldehyde; andc. contacting the aldehyde with an extender reagent to form an elongated ester.40. The method of claim 39 , further comprising transesterifying a glyceride to form the first polyunsaturated fatty acid.4143-. (canceled)44. The method of claim 40 , wherein the glyceride is derived from an algae cultured in a fermentation medium.4561-. (canceled)62. The method of claim 39 , wherein the reducing is conducted in the presence of at least one of lithium aluminum hydroxide (LAH) and tetrahydrofuran (THF).6364-. (canceled)65. The method of claim 39 , wherein the oxidizing is conducted in the presence of at least one of dimethyl sulfoxide (DMSO ...

Подробнее
25-07-2013 дата публикации

APOPTOSIS PROMOTERS

Номер: US20130190488A1
Принадлежит: ABBOTT LABORATORIES

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. 19-. (canceled)10. A compound , or a therapeutically acceptable salt thereof , wherein the compound is selected from the group consisting of:N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(5,6-dihydro-1(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(2,4-dimenthyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-methyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(4,4-dimethyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-1-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)oxy)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;4-(((1R)-3-(bis(2-methoxyethyl)amino)-1 ...

Подробнее
25-07-2013 дата публикации

FLUORESCENT SUBSTRATES FOR MONOAMINE TRANSPORTERS AS OPTICAL FALSE NEUROTRANSMITTERS

Номер: US20130190497A1

The present invention relates to compounds of the general structure: wherein Y is O, X is O, bond α is absent and bond β is present, or Y is H, X is CH, bond α is present, and bond β is absent; atom Z is a carbon and bonds χ, δ and γ are present, or is a nitrogen and bonds χ, δ and γ are absent; Ris —H, —OH, —O—R, —N(H)—R, —N(H)—(CH)—NH, —N(R)(R), or a piperazine cation; Ris either covalently bound to R, or is —H, or is covalently bound to Rso as to form a substituted or unsubstituted pyrrole or Ris covalently bound to Ror Ror R; or Rand Rare covalently joined to form an aromatic ring; Ris either covalently bound to Rso as to form a pyrrole, or is, inter alia, —H, —OH, alkyl, or when Z is nitrogen Ris ═O; Ris, inter alia, —H, —OH, or —RNH; Ris, inter alia, —H, —OH, or —RNH, and Ris either is covalently bound to Ror is —H, or Ris covalently bound to Ror Ror R. This invention also provides processes for making the compounds as well as methods for monitoring activity of monoamine transporters or treating monoamine transporter-associated diseases by employing the compounds. 2. (canceled)3. The compound of claim 1 , wherein W is a mono-substituted heterocyclyl group wherein the heteroatom is nitrogen.4. The compound of claim 1 , wherein W is a di-substituted heterocyclyl group wherein the heteroatoms are each nitrogen.5. The compound of claim 1 , wherein W is a piperazine group.6. (canceled)7. (canceled)8. (canceled)9. The compound of claim 1 , wherein Ris —H claim 1 , —CHCHNH claim 1 , —CHCHNHCH claim 1 , —CHCH(CH)NH claim 1 , —NHCHCHNH claim 1 , —CHNH claim 1 , or a piperazine group.10. The compound of claim 1 , wherein Ris —CHCHNH claim 1 , a piperazine group claim 1 , a piperazine cation claim 1 , a pyrrolidin-2-yl group claim 1 , a piperidinyl group.11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)18. (canceled)20. (canceled)22145.-. (canceled)146. The compound of claim 21 ,wherein{'sub': 1', '34', '2, 'claim-text': {'sub': 32', '3', '2', '3, ' ...

Подробнее
01-08-2013 дата публикации

METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES

Номер: US20130197072A1
Принадлежит: DAIICHI SANKYO CO., LTD.

Methods for manufacturing neuraminic acid compounds and synthetic intermediates of neuraminic acid compounds, including a method for manufacturing a compound represented by 2. The manufacturing method according to claim 1 , wherein Ris a methyl group claim 1 , Ris a methyl group claim 1 , Rand Rtogether form an oxo group claim 1 , and the Lewis acid is titanium (IV) isopropoxide.4. The manufacturing method according to claim 3 , wherein Ris a methyl group.6. The compound according to claim 5 , wherein Ris a methyl group.8. The manufacturing method according to claim 7 , wherein Ris a 1-heptyl group claim 7 , Ris a methyl group and Ris a methyl group.10. The manufacturing method according to claim 9 , wherein Ris a 1-heptyl group claim 9 , Ris a methyl group claim 9 , Ris a methyl group and X is Cl.12. (canceled)14. The compound represented by the formula (I) claim 13 , which is contained with up to 10 wt. % of the compound represented by the formula (II) claim 13 , or a pharmacologically acceptable salt thereof according to claim 13 , wherein the chemical purity of the compound represented by the formula (I) is 99 wt. % or higher.15. The compound represented by the formula (I) claim 13 , which is contained with up to 10 wt. % of the compound represented by the formula (II) claim 13 , or a pharmacologically acceptable salt thereof according to claim 13 , wherein the chemical purity of the compound represented by the formula (I) is 99.5 wt. % or higher.16. The compound represented by the formula (I) claim 13 , which optionally includes up to 10 wt. % of the compound represented by the formula (II) claim 13 , according to claim 13 , wherein Ris a 1-heptyl group and Ris a methyl group.18. A compound represented by the formula (I) claim 17 , which is optionally contained with the compound represented by the formula (II) claim 17 , or a pharmacologically acceptable salt thereof according to claim 17 , containing 0.3 wt.% or less of the compound represented by the formula ...

Подробнее
01-08-2013 дата публикации

HYPOCHOLESTEROLEMIC, ANTI-INFLAMMATORY AND ANTIEPILEPTIC NEUROPROTECTIVE COMPOUND

Номер: US20130197073A1
Принадлежит: NEURON BIOPHARMA, S.A.

The present invention describes a compound of formula (I) 112-. (canceled)14. A pharmaceutical composition comprising a compound of formula (I) according to and/or its hydroxy acid form and/or a pharmaceutically acceptable salt of said hydroxy acid and/or a pharmaceutically acceptable prodrug or solvate of the compound or of its hydroxy acid form claim 13 , and at least one pharmaceutically acceptable adjuvant claim 13 , carrier and/or vehicle.16. A method according to claim 15 , wherein the neurodegenerative diseases are: Alzheimer's disease claim 15 , Huntington's disease claim 15 , Parkinson's disease claim 15 , amyotrophic lateral sclerosis (ALS) or multiple sclerosis.17. A method of treatment according to claim 15 , wherein seladin-1/DHCR24 gene expression is increased.19. A method according to for the prevention or treatment of neuronal death associated with neurodegenerative diseases claim 18 , with undesired oxidation or with age-associated pathological processes.20. A method according to wherein the neurodegenerative diseases are Alzheimer's claim 19 , Parkinson's claim 19 , multiple sclerosis claim 19 , amyotrophic lateral sclerosis claim 19 , status epilepticus or Huntington's. The present invention relates to the prevention and/or the treatment of neurodegenerative diseases or of diseases associated with undesired oxidation or of age-associated pathological processes, as well as to the decrease of cholesterol levels and to inhibition of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase for the prevention of dyslipidemia and of cardiovascular diseases, as well as of diseases associated with acute or chronic inflammatory processes, as well as to the prevention and/or the treatment of epilepsy, epileptic seizures or convulsions.The high incidence of neurodegenerative diseases and of age-associated diseases is a problem of the first order worldwide. It is therefore necessary to search for neuroprotective compounds preventing or palliating said ...

Подробнее
01-08-2013 дата публикации

METHOD OF MAKING AZAINDAZOLE DERIVATIVES

Номер: US20130197229A1
Принадлежит:

Disclosed are methods, reagents, and intermediates useful for making azaindazole derivatives, which may be used to modulate Glucokinase. The disclosed methods and materials are generally useful for making halo-esters and sulfonyl-substituted compounds. 414-. (canceled)15. The method according to claim 1 , wherein Rand Rare each independently selected from the group consisting of Calkyl claim 1 , Ccycloalkyl claim 1 , pyrrolidinyl claim 1 , piperidinyl claim 1 , piperazinyl claim 1 , tetrahydropyranyl claim 1 , tetrahydrofuranyl claim 1 , phenyl claim 1 , pyridinyl claim 1 , and pyrazinyl claim 1 , each optionally substituted.16. The method according to claim 15 , wherein Ris cyclopropyl.17. The method according to claim 15 , wherein Ris tetrahydro-2H-pyran-4-yl.18. The method according to claim 1 , wherein Ris Calkyl.19. The method according to claim 1 , wherein Ris ethyl.20. The method according to claim 1 , wherein Gis fluoro.21. The method according to claim 1 , wherein Gis bromo.23. The method according to claim 22 , wherein Ris selected from the group consisting of Calkyl claim 22 , Ccycloalkyl claim 22 , pyrrolidinyl claim 22 , piperidinyl claim 22 , piperazinyl claim 22 , tetrahydropyranyl claim 22 , tetrahydrofuranyl claim 22 , phenyl claim 22 , pyridinyl claim 22 , and pyrazinyl claim 22 , each optionally substituted.24. The method according to claim 22 , wherein Ris cyclopropyl.25. The method according to claim 22 , wherein Gis fluoro.27. The method according to claim 26 , wherein Ris selected from the group consisting of Calkyl claim 26 , Ccycloalkyl claim 26 , pyrrolidinyl claim 26 , piperidinyl claim 26 , piperazinyl claim 26 , tetrahydropyranyl claim 26 , tetrahydrofuranyl claim 26 , phenyl claim 26 , pyridinyl claim 26 , and pyrazinyl claim 26 , each optionally substituted.28. The method according to claim 26 , wherein Ris tetrahydro-2H-pyran-4-yl.29. The method according to claim 26 , wherein Ris Calkyl.30. The method according to claim 26 , wherein ...

Подробнее
08-08-2013 дата публикации

NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS

Номер: US20130203727A1
Принадлежит: Gilead Sciences, Inc.

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I). 2. The compound of wherein Ris (C-C)alkyl claim 1 , (C-C)alkenyl or —O(C-C)alkyl wherein any (C-C)alkyl or (C-C)alkenyl of Ris optionally substituted with one or more groups selected from —O(C-C)alkyl claim 1 , halo claim 1 , oxo and —CN; and wherein Ris H.4. The compound of wherein Ris selected from:{'sub': 1', '6', '2', '6', '1', '6', '3', '7', '1', '6', '1', '6', '2', '1', '6', '1', '6', '2', '1', '6', '1', '6, 'a) aryl, heterocycle and heteroaryl, wherein any aryl, heterocycle and heteroaryl is optionally substituted with one or more groups each independently selected from halo, (C-C)alkyl, (C-C)alkenyl, (C-C)haloalkyl, (C-C)cycloalkyl, —OH, —O(C-C)alkyl, —SH, —S(C-C)alkyl, —NH, —NH(C-C)alkyl and —N((C-C)alkyl), wherein (C-C)alkyl is optionally substituted with hydroxy, —O(C-C)alkyl, cyano or oxo;'}{'sub': 3', '14', '3', '14', '3', '7, 'sup': 1', '1, 'b) (C-C)carbocycle, wherein (C-C)carbocycle is optionally substituted with one or more Zgroups, wherein two Zgroups together with the atom or atoms to which they are attached optionally form a (C-C)carbocycle or heterocycle; and'}{'sup': 7', '1, 'c) aryl, heteroaryl and fused-heterocycle, wherein any aryl, heteroaryl and fused-heterocycle is substituted with one or more Zgroups and optionally substituted with one or more Zgroups.'}5. The compound of wherein Ris selected from:{'sub': 1', '6', '2', '6', '1', '6', '3', '7', '1', '6', '1', '6', '2', '1', '6', '1', '6', '2', '1', '6', '1', '6, 'a) aryl, heterocycle and heteroaryl, wherein any aryl, heterocycle and ...

Подробнее
08-08-2013 дата публикации

MILD CATIONIC MITOCHONDRIAL UNCOUPLERS

Номер: US20130203843A1
Принадлежит: LIMITED LIABILITY COMPANY MITOTECH

The present invention relates to biology and medicine and in particular can be used in medicine for the preparation of a pharmaceutical composition for the specific, self-regulating uncoupling of mitochondria. The invention can be useful in the treatment of diseases and conditions associated with the disruption of cellular metabolism, in the treatment of obesity, including pathological forms thereof, and also for the treatment of diseases associated with the increased formation of free radicals and reactive oxygen species. 5. Application of compositions claimed in for manufacturing of a pharmaceutical composition for reducing the amount of free radicals and reactive oxygen species in a cell.6. Application of compositions claimed in for manufacturing of a pharmaceutical composition for stimulating cell metabolism.7. Application according to claim 5 , when a cell claim 5 , being normal or cancer claim 5 , or stem cell claim 5 , is in a human or other mammal; is a plant cell and/or is part of a plant at any stage of its development including genetically modified one; is in a culture of plant cells or protoplasts; is a fungal cell and/or in a culture of fungal cells; including to increase viability and/or productivity of cells producing preparations claim 5 , pharmacologically applicable proteins claim 5 , peptides claim 5 , antibodies.8. Application according to for treatment of obesity including pathological forms thereof claim 7 , and also for treatment of diseases associated with a metabolic disorder.9. Application according to for treatment of diabetes claim 7 , complications caused by diabetes and also for treatment of diseases with concomitant diabetes.10. Application according to for treatment of a disease claim 7 , at which a decrease in the amount of free radicals and reactive oxygen species in an organism is useful.11. Application according to for protection of healthy cells from damage during chemotherapy claim 7 , radiotherapy or photodynamic therapy of ...

Подробнее
15-08-2013 дата публикации

PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUNDS

Номер: US20130211098A1
Автор: Rapta Miroslav
Принадлежит:

The invention provides processes for preparing intermediates useful for preparing compounds of the formula: 2. The process of claim 1 , where the ether solvent is 2-methyltetrahydrofuran.3. The process of claim 2 , where the ether solvent further comprises cyclopentyl methyl ether.5. The process of claim 4 , where acidic deprotection is conducted with 3M HCl.6. The process of claim 4 , where Pis selected from acetyl claim 4 , adamantyl-oxycarbonyl claim 4 , t-amyloxycarbonyl claim 4 , benzothiophene sulfone-2-methoxycarbonyl claim 4 , benzoyl claim 4 , benzyl claim 4 , benzyloxycarbonyl claim 4 , 2-(p-biphenylyl)propyl-2-oxycarbonyl claim 4 , t-butoxycarbonyl claim 4 , 2-(t-butylsulfonyl)-2-propenyloxycarbonyl claim 4 , 3 claim 4 ,4-dimethoxybenzyl claim 4 , 2 claim 4 ,2-dimethyl-3 claim 4 ,5-dimethyloxybenzyloxycarbonyl claim 4 , dithiasuccinoyl claim 4 , formyl claim 4 , 9-fluorenylmethoxycarbonyl claim 4 , 2-furanmethyloxycarbonyl claim 4 , p-methoxybenzyl claim 4 , p-methoxybenzyl carbonyl claim 4 , 1-methylcyclobutyloxycarbonyl claim 4 , o-nitrophenylsulfenyl claim 4 , 2-phenylpropyl-2-oxycarbonyl claim 4 , 2-(p-phenylazophenyl)propyl-2-oxycarbonyl claim 4 , silyl ethers claim 4 , tosyl claim 4 , trifluoroacetyl claim 4 , β-trimethylsilylethyloxycarbonyl claim 4 , triphenylmethyl claim 4 , and trityl.7. The process of claim 6 , where Pis t-butoxycarbonyl.9. The process of claim 8 , where step (a) is conducted with isobutyl chloroformate in the presence of a tertiary amine base.10. The process of claim 9 , where the tertiary amine base is N-methylmorpholine.11. The process of claim 8 , where the reducing agent is sodium tetrahydroborate.13. The compound of claim 12 , where Pis selected from acetyl claim 12 , benzoyl claim 12 , benzyl claim 12 , p-methoxybenzyl ether claim 12 , β-methoxyethoxymethyl ether claim 12 , methylthiomethyl ether claim 12 , pivaloyl claim 12 , silyl ethers claim 12 , tetrahydropyranyl claim 12 , triphenylmethyl claim 12 , and trityl.14. ...

Подробнее
22-08-2013 дата публикации

Selective Androgen Receptor Modulators

Номер: US20130217762A1
Принадлежит: ELI LILLY AND COMPANY

The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof. 6. A compound of that is 2-chloro-4-[[(1R claim 5 ,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile.8. A compound of that is 2-Chloro-4-[[(1S claim 7 ,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile.9. A pharmaceutical composition comprising a compound of any of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more pharmaceutically acceptable carriers claim 1 , diluents claim 1 , or excipients.10. A pharmaceutical composition comprising a compound of any of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , and one or more pharmaceutically acceptable carriers claim 5 , diluents claim 5 , or excipients.11. A pharmaceutical composition comprising a compound of any of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , and one or more pharmaceutically acceptable carriers claim 7 , diluents claim 7 , or excipients.12. A pharmaceutical composition according to which is formulated as a patch.13. A pharmaceutical composition according to which is formulated as a topical gel.14. A pharmaceutical composition according to which is formulated as a topical cream.15. A pharmaceutical composition according to which is formulated as a topical spray.16. A pharmaceutical composition according to comprising a solvate.17. A pharmaceutical composition according to which is 2-chloro-4-[[(1R claim 16 ,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile•ethanol solvate in crystalline form characterized by an X-ray powder diffraction pattern obtained from a CuKα source (λ=X Å) which comprises peaks at:a) 7.00, 17.26, 12.30, and 23.34+/−−0.2 in 2θ; orb) 7.00, 8.59, 12.30, 16.76, 17.26, and 23.34+/−−0.2 in 2θ; orc) 7.00, 8.59, 10.13, 11.89, 12.30, 12.91, 13.95, 16.76, 17.26, 23.34+/−−0.2 in 2θ.18. A method for the treatment of muscle atrophy in a patient ...

Подробнее
22-08-2013 дата публикации

Entecavir synthesis method and intermediate compound thereof

Номер: US20130217879A1
Автор: Zhiguo Zheng
Принадлежит: AUSUN PHARMATECH CO Ltd

The present invention relates to a preparation method for a medicine and an intermediate compound thereof, specifically, relates to a preparation method for entecavir, an intermediate compound thereof, and a synthesis method for the intermediate compound.

Подробнее
22-08-2013 дата публикации

METHOD FOR MANUFACTURING ESTER

Номер: US20130217898A1

The present invention relates to a method for manufacturing an ester from a ketone or an aldehyde, which is a reactive substrate, by a Baeyer-Villiger oxidation reaction using hydrogen peroxide, and in this method, as a catalyst, M(BAr), which is a metal borate, is used (M represents an alkali metal or an alkaline earth metal; Ar represents an aryl; and n is the same number as the valence of M). For example, when cyclohexanone was used as the reactive substrate, and Sr[B(3,5-CFCH)]was used as the catalyst, ε-caprolactone was obtained at an isolated yield of 82%. 1. A method for manufacturing an ester from a ketone or an aldehyde , which is a reactive substrate , by a Baeyer-Villiger oxidation reaction using hydrogen peroxide ,{'sub': 4', 'n, "wherein M(BAr), which is a borate salt, is used as a catalyst (M represents an alkali metal, an alkaline earth metal, or a triarylmethyl; four Ar's each represent an aryl having an electron withdrawing group and are identical to or different from each other; and n is the same number as the valence of M)."}2. The method for manufacturing an ester according to claim 1 ,wherein Ar of the borate salt represents pentafluorophenyl or 3,5-bistrifluoromethylphenyl.3. The method for manufacturing an ester according to claim 1 ,wherein the catalyst is used in an amount of 0.1 to 5 percent by mole with respect to that of the reactive substrate.4. The method for manufacturing an ester according towherein the reactive substrate has a carbon-carbon double bond, a carbon-carbon triple bond, a halogen group, a hydroxyl group, a silyl group, or a siloxy group.5. The method for manufacturing an ester according to claim 1 ,wherein the reactive substrate comprises a cyclic ketone, a chain ketone, a chromanone, or an aromatic aldehyde.6. The method for manufacturing an ester according to claim 1 ,wherein the method uses a Brønsted acid as a promoter.7. The method for manufacturing an ester according to claim 6 ,wherein the promoter comprises a ...

Подробнее
22-08-2013 дата публикации

CHIRAL INTERMEDIATES USEFUL FOR THE PREPARATION OF HYDROXYPHOSPHINE LIGANDS

Номер: US20130217900A1
Принадлежит: UNITED PHOSPHORUS LIMITED

A compound of formula (I), wherein Ris hydrogen or a hydroxyl protecting group; and Rand Rare same or different and are independently selected from halogen or —O—SO—X; wherein X is —C-Calkyl; C-Calkyl substituted with one or more halogen; or substituted or unsubstituted phenyl wherein said phenyl substituent is selected from halogen, nitro and C-Calkyl; provided that when Ris bromine, X is not p-toluoyl; and a process for the preparation thereof. 3. The compound as claimed in claim 2 , wherein said hydroxyl protecting group is selected from Z or —SO—X.4. The compound as claimed in or claim 2 , wherein Rand Rare same or different and are independently selected from halogen or —O—SO—X provided that when Ris bromine claim 2 , X is not p-toluoyl.5. The compound as claimed in or claim 2 , wherein X is selected from C-Calkyl; C-Calkyl substituted with one or more halogen; and substituted or unsubstituted phenyl wherein said phenyl substituent is selected from halogen claim 2 , nitro and C-Calkyl.7. The compound as claimed in claim 4 , wherein said Rand Rare same or different and are independently selected from F claim 4 , Cl claim 4 , Br claim 4 , I or —O—SO—X.8. The compound as claimed in claim 7 , wherein X is selected from methyl claim 7 , trifluoromethyl claim 7 , n-novafluorobutyl claim 7 , 2 claim 7 ,2 claim 7 ,2-trifluoroethyl claim 7 , p-toluoyl claim 7 , p-nitrophenyl and p-bromophenyl.10. The compound as claimed in or claim 7 , wherein Rand Rare same or different and are independently selected from F claim 7 , Cl claim 7 , Br and I.11. The compound as claimed in or or claim 7 , wherein Z is selected from tetrahydro-2H-pyran-2-yl; tetrahydro-2H-pyran-2-one-3-yl; tetrahydro-2H-pyran-2-methoxy-6-yl and tetrahydro-2H-pyran-2-ethoxy-6-yl.13. Use of a compound as claimed in any preceding claim as an intermediate for the preparation of a hydroxyphosphine ligand.1515. Use of a hydroxyphosphine ligand as a co-catalytic ligand for the enantioselective preparation of a ...

Подробнее
05-09-2013 дата публикации

Fluorinated monomer of cyclic acetal structure, polymer, resist protective coating composition, resist composition, and patterning process

Номер: US20130231491A1
Принадлежит: Shin Etsu Chemical Co Ltd

A fluorinated monomer of cyclic acetal structure has formula (1) wherein R is a C 1 -C 20 alkyl group which may be substituted with halogen or separated by oxygen or carbonyl, and Z is a divalent organic group which forms a ring with alkylenoxy and contains a polymerizable unsaturated group. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water sliding property, lipophilicity, acid lability and hydrolyzability and is useful in formulating a protective coating composition and a resist composition.

Подробнее
12-09-2013 дата публикации

ANTIBACTERIAL AGENTS: HIGH-POTENCY MYXOPYRONIN DERIVATIVES

Номер: US20130237595A1
Принадлежит:

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Ya, Yb, R1, R2, and G are as described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as inhibitors of bacterial RNA polymerase and as antibacterial agents. 2. The compound of wherein:{'sup': '2', 'Ris hydrogen;'}{'sup': a', 'b', 'a', 'b', 'a', 'b, 'sub': 1', '4', '1', '10', '2', '12', '2', '12', '2', '12, 'one of Yand Yis hydrogen or C-Cstraight alkyl, and the other of Yand Yis C-Cstraight or branched alkyl, C-Cstraight or branched hydroxyalkyl, C-Cstraight or branched alkenyl, C-Cstraight or branched hydroxyalkenyl, or Yand Yare taken together with their intervening atom to form a 4-6 membered ring having 0-1 ring heteroatoms selected from nitrogen, oxygen or sulfur;'}{'sup': 3', '3', '3', '3', '3', '3, 'sub': 2', '2', '2', '2', '2', '2, 'G is —CH═CH—NHC(O)—R, —CH═CH—NHC(S)—R, —CHCHNHC(O)—R, —CHCHNHC(S)—R, —CHNHNHC(O)—R, or —CHNHNHC(S)—R;'}{'sup': 3', '4, 'sub': 1', '6', '1', '6', '1', '6', '2, 'Ris C-Calkyl, —O(C-Calkyl), —S(C-Calkyl), or —N(R); and'}{'sup': 4', '4, 'sub': 1', '6, 'one Ris hydrogen and the other Ris hydrogen or —C-Calkyl.'}3. The compound of wherein:{'sup': a', 'b', 'a', 'b, 'sub': 3', '2', '3', '1', '10', '2', '12', '2', '12', '2', '12, 'one of Yand Yis hydrogen, —CH, or —CHCH, and the other of Yand Yis C-Cstraight or branched alkyl, C-Cstraight or branched hydroxyalkyl, C-Cstraight or branched alkenyl or C-Cstraight or branched hydroxyalkenyl;'}{'sup': 3', '3', '3, 'sub': 2', '2', '2, 'G is —CH═CH—NHC(O)—R, —CHCHNHC(O)—R, or —CHNHNHC(O)—R;'}{'sup': 3', '4, 'sub': 1', '6', '1', '6', '2, 'Ris C-Calkyl, —O(C-Calkyl), or —N(R); and'}{'sup': 4', '4, 'sub': 1', '4, 'one Ris hydrogen and the other Ris hydrogen or —C-Calkyl.'}4. The compound of wherein:{'sup': a', 'b', 'a', 'b, 'sub': 3', '1', '10', '3', '2', '2', 't', '2', '2', '3', '2', '2', 't', '2', '2', '3', '2', 't', '2', '3', '2', '3 ...

Подробнее
19-09-2013 дата публикации

NATURAL PRODUCT ANTIBIOTICS AND ANALOGS THEREOF

Номер: US20130245130A1
Принадлежит:

Provided herein are pure and isolated natural products and analogs thereof of Formula (I), (II), (III), and (IV), pharmaceutical compositions thereof, and methods of use, for example, for treating a bacterial infection. Further provided are methods useful in identifying an inhibitor of bacterial sugar fermentation in a bacterial strain, such as a compound (inhibitor) of Formula (I), (II), (III), or (IV): 5Escherichia coli, Pseudomonas aeruginosa, Vibrio cholerae, K. pneumoniaeStaphylococcus aureusMycobacterium tuberculosis. The method of claim 4 , wherein the bacterial infection is an claim 4 , methicillin-resistant claim 4 , or infection.715-. (canceled)1730-. (canceled)31. The pure and isolated compound of claim 1 , wherein Ris hydrogen.32. The pure and isolated compound of claim 1 , wherein Ris hydrogen.33. The pure and isolated compound of claim 1 , wherein Ris substituted or unsubstituted C-Calkyl.34. The pure and isolated compound of claim 1 , wherein at least one instance of Rand Ris hydrogen.35. The pure and isolated compound of claim 1 , wherein each instance of Rand Ris hydrogen.36. The pure and isolated compound of claim 1 , wherein Rand Rare the same group.37. The pure and isolated compound of claim 1 , wherein each of Rand Rare independently hydrogen or —C(═O)CH.38. The pure and isolated compound of claim 1 , wherein each of R claim 1 , R claim 1 , and Rare the same group.39. The pure and isolated compound of claim 1 , wherein each of R claim 1 , R claim 1 , and Rare independently hydrogen or —C(═O)CH. The present application claims the benefit under 35 U.S.C. §119(e) of U.S. provisional patent application, U.S. Ser. No. 61/602,304, filed Feb. 23, 2012, which is incorporated herein by reference.The emergence of bacteria with resistance to multiple antimicrobial agents has increased the need to discover new antibiotics.The emergence of bacteria with resistance to multiple anti-microbial agents has motivated the development of high throughput chemical ...

Подробнее
19-09-2013 дата публикации

Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae

Номер: US20130245284A1
Принадлежит:

Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition. 2. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.3. The compound of wherein Ris selected from mono- and polyfluoro-substituted arylalkyl moieties.4. The compound of wherein Ris selected from mono- and difluoro-substituted benzyl moieties.5. The compound of in at least one of human plasma and contact with an enzyme in a streptococcal mevalonate biosynthetic pathway.7. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.8. The compound of wherein Ris selected from aryl claim 7 , mono- and polyfluoroaryl claim 7 , arylalkyl claim 7 , mono- and polyfluoroarylalkyl moieties.9. The compound of wherein Ris selected from phenyl claim 8 , mono- and polyfluorophenyl claim 8 , benzyl claim 8 , monofluorobenzyl and polyfluorobenzyl moieties.11. The compound of wherein X is selected from NH and O; and Ris independently selected from fluoromethyl and trifluoromethyl moieties.12. The compound of where Ris selected from arylalkyl claim 11 , mono- and polyfluoro-substituted arylalkyl moieties.13. The compound of wherein Rand Rare independently selected from H and alkyl moieties.14. The compound of wherein at least one of Rand Ris methyl.16. The compound of wherein X is selected from NH and O; and Ris selected from fluoromethyl and trifluoromethyl moieties.17. The compound of wherein Ris selected from alkyl claim 16 , mono- and polyfluoro-substituted alkyl claim 16 , aryl claim 16 , mono- and polyfluoro-substituted aryl claim 16 , arylalkyl claim 16 , mono- and polyfluoro-substituted arylalkyl moieties.18. The compound of wherein X is O; Ris selected from alkyl claim 15 , aryl and arylalkyl moieties; and Rand Rare independently selected from H and acetyl moieties.19. The compound of wherein at least one of Rand Ris acetyl.21. The compound of ...

Подробнее
26-09-2013 дата публикации

NOVEL HERBICIDE

Номер: US20130252811A1
Принадлежит: SYNGENTA LIMITED

Herbicidal composition comprising a pyrandione herbicide and a co-herbicide The present invention relates to a herbicidal composition comprising as active ingredient a mixture of a) a herbicidally effective amount of a compound of formula (I) wherein: Ris methyl, ethyl, n-propyl, halogen, difluoromethoxy, trifluoromethoxy or trifluoromethyl, Ris phenyl or phenyl substituted by C-Calkyl, C-Chaloalkyl, C-Calkoxy, C-Chaloalkoxy or halogen, R, R, Rand R, independently of each other, are hydrogen or C-Calkyl, Y is O, and G is hydrogen, an alkali metal, alkaline earth metal, sulfonium, or ammonium, or G is a latentiating group which is C(O)—Ror C(0)-O—R; and b) a co-herbicide selected from the group consisting of fenoxasulfone, ipfencarbazone, propyrisulfuron, and N-[2-[(4,6-dimethoxy-1,3,5-triazin-2-yl)carbonyl]-6-fluorophenyl]-1,1-difluoro-N-methylmethanesulfonamide. The herbicidal composition is typically for controlling grasses and weeds in crops of useful plants, especially for controlling and/or weeds in crops of rice. 2. A herbicidal composition as claimed in claim 1 , wherein Ris ethyl.3. A herbicidal composition as claimed in claim 1 , wherein Ris phenyl substituted by methyl claim 1 , methoxy claim 1 , or halogen.4. A herbicidal composition as claimed in claim 3 , wherein Ris phenyl substituted by fluorine or chlorine.5. A herbicidal composition as claimed in claim 1 , wherein R claim 1 , R claim 1 , Rand R claim 1 , independently of each other claim 1 , are hydrogen or C-Calkyl.6. A herbicidal composition as claimed in claim 5 , wherein R claim 5 , R claim 5 , Rand Rare methyl.7. A herbicidal composition as claimed in claim 1 , wherein G is hydrogen claim 1 , C(O)—Ror C(O)—O—R; wherein Rand Rare C-Calkyl.8. A herbicidal composition as claimed in claim 7 , wherein G is hydrogen claim 7 , C(O)—Ror C(O)—O—R; wherein Rand Rare methyl claim 7 , ethyl claim 7 , n-propyl claim 7 , isopropyl or t-butyl.9. A herbicidal composition as claimed in claim 8 , wherein G is ...

Подробнее
03-10-2013 дата публикации

Radiation-sensitive resin composition, pattern-forming method, polymer, and compound

Номер: US20130260315A1
Принадлежит: JSR Corp

A radiation-sensitive resin composition includes a polymer component that includes one or more types of polymers, and a radiation-sensitive acid generator. At least one type of the polymer of the polymer component includes a first structural unit represented by a following formula (1). R 1 represents a hydrogen atom, a fluorine atom, a methyl group or a trifluoromethyl group. R 2 represents a linear alkyl group having 5 to 21 carbon atoms. Z represents a divalent alicyclic hydrocarbon group or an aliphatic heterocyclic group having a ring skeleton which has 4 to 20 atoms. A part or all of hydrogen atoms included in the alicyclic hydrocarbon group and the aliphatic heterocyclic group represented by Z are not substituted or substituted.

Подробнее
03-10-2013 дата публикации

2-PYRONES

Номер: US20130261175A1
Принадлежит: Merck Patent GmBH

The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I). 2. A method according to for the prevention claim 1 , reduction or combating of cellulite or signs of cellulite and/or for the reduction of local fat accumulation.3. A method according to for prophylaxis against or combating of time- and/or light-induced ageing processes of the skin or hair.4. A method according to for prophylaxis against or reduction of skin unevenness claim 1 , such as wrinkles claim 1 , fine lines claim 1 , rough skin or large-pored skin.5. A method according to for the stimulation of lipolysis.6. A method according to claim 1 , characterised in that R1 stands for a straight-chain or branched C- to C-alkyl group.7. A method according to claim 1 , characterised in that R2 stands for H or a straight-chain or branched C1- to C6-alkyl group.8. A method according to claim 1 , characterised in that R4 stands for H or a straight-chain or branched C2- to C20-alkenyl group having one or more double bonds.9. A method according to claim 1 , characterised in that R3 stands for a radical selected fromH,{'sub': 1', '20, 'straight-chain or branched C- to C-alkyl group,'}{'sub': 2', '20, 'straight-chain or branched C- to C-alkenyl group having one or more double bonds, where the alkenyl group may also be substituted by one or more saturated or unsaturated cyclohexyl groups,'}an acyl radical of the formula —C(═O)—R6.10. A method according to claim 1 , characterised in that the radicals R5 are selected claim 1 , independently of one another claim 1 , from H claim 1 , OH or straight-chain or branched O—(C1- to C6-alkyl).13. A composition according to claim 12 , characterised in that the at least one compound of the formula (I) is present in an amount of 0.01 to 20% by weight.14. A process for the preparation of a composition ...

Подробнее
10-10-2013 дата публикации

Compound

Номер: US20130267586A1
Принадлежит: ANTOXIS LIMITED

The present invention provides compounds of the formula Formula I or a salt thereof: and the uses of such compounds for the treatment of a disease or disorder involving oxidative damage, for preventing UV damage to the skin of a mammal and for preventing or reversing the effects of ageing, or for treating or preventing dry skin. 2. A compound as claimed in claim 1 , wherein:{'sub': '20', 'Rrepresents H or a 3, 4, 5, 6, 7 or 8 membered saturated or unsaturated ring (Ring D);'}{'sub': '21', 'claim-text': i) represents H;', {'sub': '22', 'sup': 1', '2, 'ii) together with Rprovides a second bond between Cand C; or'}, {'sub': 1', '1', '1-6', '21', '1, 'sup': '1', 'iii) when X is —NR— and Ris not H or Calkyl, Rtogether with Rprovides a second bond between Cand N;'}], 'R{'sub': '22', 'claim-text': i) represents H;', {'sub': '23', 'ii) together with Rforms ═O; or'}, {'sub': '21', 'sup': 1', '2, 'iii) together with Rprovides a second bond between Cand C;'}], 'R{'sub': '23', 'claim-text': i) represents H or a 3, 4, 5, 6, 7 or 8 membered saturated or unsaturated ring (Ring D); or', {'sub': '22', 'ii) together with Rforms ═O;'}, {'sub': 20', '23, 'wherein at least one of Rand Ris a 3, 4, 5, 6, 7 or 8 membered saturated or unsaturated ring (Ring D).'}], 'R3. (canceled)4. (canceled)5. A compound as claimed in claim 1 , wherein:{'sub': 20', '21', '22', '23, 'sup': 1', '2, 'R, R, R, and Rform part of a 5, 6 or 7 membered unsaturated ring including Cand C, which ring (Ring A) is substituted with at least one group;'}said at least one group being a 3, 4, 5, 6, 7 or 8 membered saturated or unsaturated ring (Ring D); and{'sup': '1', 'wherein the 3, 4, 5, 6, 7 or 8 membered saturated or unsaturated ring (Ring D) is at the meta, para or ortho position relative to C.'}6. A compound as claimed in claim 5 , wherein the 3 claim 5 , 4 claim 5 , 5 claim 5 , 6 claim 5 , 7 or 8 membered saturated or unsaturated ring (Ring D) is at the meta position relative to C.7. A compound as claimed in claim ...

Подробнее
24-10-2013 дата публикации

HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA

Номер: US20130281366A1
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. 2. The compounds as claimed in wherein ‘A’ is selected from optionally substituted aryl or heterocyclyl groups.3. The compounds as claimed in wherein when ‘A’ represents aryl group the aryl groups is selected from substituted or unsubstituted monocyclic or bicyclic aromatic groups.4. The compound as claimed in wherein the aryl group is an optionally substituted phenyl group.5. The compound as claimed in wherein when ‘A’ represents heterocyclyl group claim 1 , the heterocyclyl group is selected from single or fused mono claim 1 , bi or tricyclic aromatic or non-aromatic groups containing one or more hetero atoms selected from O claim 1 , N or S.65. The compound as claimed in wherein the heterocyclyl group is selected from pyridyl claim 1 , thienyl claim 1 , furyl claim 1 , pyrrolyl claim 1 , oxazolyl claim 1 , thiazolyl claim 1 , isothiazolyl claim 1 , imidazolyl claim 1 , isoxazolyl claim 1 , oxadiazolyl claim 1 , thiadiazolyl claim 1 , triazolyl claim 1 , tetrazolyl claim 1 , benzofuranyl claim 1 , benzothienyl claim 1 , indolinyl claim 1 , indolyl claim 1 , azaindolyl claim 1 , azaindolinyl claim 1 , pyrazolopyrimidinyl claim 1 , azaquinazolinyl claim 1 , pyridofuranyl claim 1 , pyridothienyl claim 1 , thienopyrimidyl claim 1 , quinolinyl claim 1 , pyrimidinyl claim 1 , pyrazolyl claim 1 , quinazolinyl claim 1 , pyridazinyl claim 1 , triazinyl claim 1 , benzimidazolyl claim 1 , benzotriazolyl claim 1 , phthalazynil claim 1 , naphthylidinyl claim 1 , purinyl claim 1 , carbazolyl claim 1 , phenothiazinyl claim 1 , phenoxazinyl claim 1 , benzoxazolyl claim 1 , benzothiazolyl claim 1 , thiazepinyl claim 1 , oxazolidinyl claim 1 , thiazolidinyl claim 1 , ...

Подробнее
24-10-2013 дата публикации

MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS

Номер: US20130281393A1
Принадлежит:

The present invention provides novel and advantageous materials and methods for preventing and treating viral infection. 14. A therapeutic composition claim 1 , comprising a compound of claim 1 , including salts thereof claim 1 , and a pharmaceutically acceptable carrier.15. A method for preventing and/or treating a viral infection claim 1 , comprising administering claim 1 , to a subject in need of such prevention and/or treatment claim 1 , an effective amount of a compound of claim 1 , including salts thereof.16. The method of claim 15 , used to prevent or treat an influenza virus infection. This application claims the benefit of U.S. provisional application Ser. No. 61/636,184, filed Apr. 20, 2012, which is incorporated herein by reference in its entirety.Viral infections are responsible for many acute and chronic life-threatening diseases. It is estimated that about 33.4 million people are living with human immunodeficiency virus (HIV) worldwide. In addition, an estimated 2 billion people have been infected with hepatitis B virus, and 600,000 people die each year due to the acute or chronic consequences of the infection. Influenza is one of the most widely spread viral infections worldwide. Major influenza A pandemics include the Asian flu pandemic in 1957 (H2N2), the Hong Kong flu pandemic in 1968 (H3N2), the re-emergence of H1N1 (Russian flu) in 1970, the H5N1 bird flu in 1997 and 2003, and the outbreak of the swine flu (H1N1) in April 2009.Despite extensive efforts, the development of effective anti-viral drugs has largely been empirical. Further, as virus strains change over time, the emergence of resistant mutants further diminishes the efficacy of existing anti-viral agents. Therefore, the development of additional novel anti-viral therapeutics is needed.The present invention provides novel and advantageous materials and methods for preventing and/or treating viral infection.In one embodiment, the present invention provides compounds of formula I, having ...

Подробнее
24-10-2013 дата публикации

Novel ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof

Номер: US20130281664A1
Принадлежит: Yeda Research and Development Co Ltd

The present invention relates to novel Ruthenium catalysts and related borohydride complexes, and the use of such catalysts, inter alia, for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to the novel uses of certain pyridine Ruthenium catalysts.

Подробнее
31-10-2013 дата публикации

DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES

Номер: US20130289003A1
Принадлежит:

A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. 4. A compound of claim 1 , wherein Ris hydrogen claim 1 , —C(O)OH claim 1 , or —C(O)OCH claim 1 , or a pharmaceutically acceptable salt thereof.5. A compound of claim 1 , wherein Ris hydrogen claim 1 , or a pharmaceutically acceptable salt thereof.6. A compound of claim 1 , wherein Ris —CDCalkyl claim 1 , —C(CH) claim 1 , —CHCH claim 1 , or —CH(CH).8. A compound of claim 1 , wherein Ris hydrogen claim 1 , —CH claim 1 , C(O)OCH claim 1 , —C(O)OH claim 1 , phenyl claim 1 , or a pharmaceutically acceptable salt thereof.9. A compound of claim 1 , wherein Ris hydrogen or —CH claim 1 , or a pharmaceutically acceptable salt thereof.10. A compound of claim 1 , wherein Rand Rare attached to the same carbon atom and together form ═O claim 1 , or a pharmaceutically acceptable salt thereof.16. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —CHor —CH.17. A compound of claim 1 , wherein Rand R claim 1 , together with the N atom to which they are attached claim 1 , form a 5- or 6-membered heterocyclic ring containing 1 N atom claim 1 , which ring is unsubstituted or substituted with —CHOH.18. A compound of claim 1 , wherein Rtogether with R claim 1 , forms ═O.19. A compound of claim 1 , which is{'sup': '2', 'O-[(3R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]1-(N-tert-butyl-N-methylamino)diazen-1-ium-1,2-diolate,'}{'sup': '2', 'O-[(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]1-(N-tert-butyl-N-methylamino)diazen-1-ium-1,2-diolate,'}{'sup': '2', 'O-[(3R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]1-(N-tert-butyl-N-ethylamino)diazen-1-ium-1,2-diolate,'}{'sup': '2', 'O-[(3R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]1-(N-tert-butyl-N- ...

Подробнее
07-11-2013 дата публикации

BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES

Номер: US20130296295A1
Принадлежит:

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. 6. The method of claim 1 , wherein the compound is selected from the group consisting of:4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-2-phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;2-(benzyloxy)-4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(2-phenylethoxy)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylthio)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(phenylthio)-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(phenylthio)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfonyl)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfinyl)benzamide;2-benzyl-4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;2-benzyl-4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;2-benzyl-4-(4-((4′-chloro-1,1′-biphenyl-2-yl) ...

Подробнее
07-11-2013 дата публикации

ARYLPROPIONYL-ALPHA-PYRONE ANTIBACTERIAL AGENTS

Номер: US20130296421A1
Автор: Ebright Richard H.
Принадлежит:

The invention provides a compound of formula (I): or a salt thereof, wherein R-Rhave any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents. 2. The compound of wherein Ris H or methyl; and Ris H or methyl.3. The compound of wherein Ris phenyl which is optionally substituted with one or more groups independently selected from halo claim 1 , hydroxy claim 1 , carboxy claim 1 , cyano claim 1 , nitro claim 1 , trifluoromethyl claim 1 , trifluoromethoxy claim 1 , (C-C)alkyl claim 1 , (C-C)alkoxy claim 1 , (C-C)alkoxycarbonyl claim 1 , (C-C)alkanoyloxy claim 1 , aryl claim 1 , heteroaryl claim 1 , aryloxy claim 1 , heteroaryloxy claim 1 , and —NRR.4. The compound of wherein Ris phenyl.5. The compound of wherein Ris n-butyl claim 1 , or i-pentyl.7. A composition comprising a compound of formula I as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable vehicle.8. A method for inhibiting a bacterial RNA polymerase comprising contacting the bacterial RNA polymerase with a compound of formula I as described in claim 1 , or a salt thereof.9. A method for inhibiting the growth of a bacterium comprising contacting the bacterium with a compound of formula I as described in claim 1 , or a salt thereof.10. A method for treating a bacterial infection in a mammal comprising administering to the mammal an effective amount of a compound of formula I as described in claim 1 , or a pharmaceutically acceptable salt thereof.1112-. (canceled)13Mycobacterium tuberculosis, Staphylococcus aureusEnterococcus faecalis, Enterococcus faeciumEscherichia coli. The method of claim 10 , wherein the bacteria is selected from MSSA and MRSA claim 10 , claim 10 , and D21f21tolC.1415-. (canceled) This application claims priority to U.S. Provisional Application No. 61/381,109, filed 9 Sep. 2010.The invention described herein was made with United ...

Подробнее
07-11-2013 дата публикации

Cyanoenamines and Their use as Fungicides

Номер: US20130298291A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to cyanoenamine derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions. 2. A composition for controlling an unwanted microorganism or insect claim 1 , comprising at least one compound according to claim 1 , and one or more extenders and/or surfactants.3. A compound according to claim 1 , capable of being used for controlling unwanted microorganisms and insects.4. A method for controlling an unwanted microorganism claim 1 , comprising applying a compound according to claim 1 , to the microorganisms and/or a habitat thereof.5. A process for preparing a composition for controlling an unwanted microorganism claim 1 , comprising mixing a compound according to claim 1 , with one or more extenders and/or surfactants.6. A compound according to claim 1 , capable of being used for treating transgenic plants.7. A transgenic plant that has been treated with a compound of .8. A method for treating a transgenic plant complying treating said plant with a compound of . The present invention relates to cyanoenamine derivatives, their process of preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions.In WO 01/85673 arylcyanoenaminones of general formula:are described, wherein K represents an oxygen or sulphur atom, Ar represents an optionally substituted aryl or heteroaryl, X may represent a cyano group, Z represents an optionally substituted phenyl or naphthyl and Y represents an optionally substituted alkyl chain. However, there is no disclosure or suggestion in this documents of any derivative wherein Ar ...

Подробнее
14-11-2013 дата публикации

Substituted 2-Aminoacetamides and the Use Thereof

Номер: US20130303568A1
Принадлежит:

The invention is directed to substituted 2-aminoacetamides represented by formula (II): 2. The method according to claim 1 , wherein A1 and A2 are both optionally substituted aryl moieties.3. The method according to claim 1 , wherein{'sub': 1', '2', '2', '1-6', '1-4, 'Aand Aare phenyl moieties, that Ais optionally substituted by one or two substituents independently selected from the group consisting of hydrogen, Calkyl, halogen, hydroxy, Calkoxy or trifluoromethyl;'}{'sub': 1', '2, 'Rand Rare hydrogen;'}{'sub': 3', '4, 'Rand Rare methyl;'}{'sub': 5', '6', '7', '1-6', '3-7, 'R, Rand Rare independently hydrogen, Calkyl, or Ccycloalkyl; and'}{'sub': '2', 'X is O, S, CH, or NH.'}4. The method according to claim 1 , wherein said compound is selected from the group consisting of:2-(4-(2-fluorobenzyloxy)benzylamino)-2-methyl-propanamide;2-(4-(4-fluorophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(3,4-methylenedioxyphenoxy)benzylamino)-2-methyl-propanamide;2-(4-(3,4-methylenedioxybenzyloxy)benzylamino)-2-methyl-propanamide;2-(4-cyclohexyloxybenzylamino)-2-methyl-propanamide;2-(4-(5,6,7,8-tetrahydro-2-naphthoxy)benzylamino)-2-methyl-propanamide;2-(4-(2-adamantanoxy)benzylamino)-2-methyl-propanamide;2-(4-(4-chloro-2-fluorophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(2,4-difluorophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(3,4-difluorophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(6-bromo-4-fluorophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(4-nitrophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(4-tetrahydropyranoxy)benzylamino)-2-methyl-propanamide;2-(4-(3,5-difluorophenoxy)benzylamino)-2-methyl-propanamide,2-(4-(4-chlorophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(4-methylphenoxy)benzylamino)-2-methyl-propanamide;2-(4-(2-chloro-4-fluorophenoxy)benzylamino)-2-methyl-propanamide;2-(4-(5-indanoxy)benzylamino)-2-methyl-propanamide;2-(4-cycloheptoxybenzylamino)-2-methyl-propanamide;2-(4-(1-methyl-4-piperidinoxy)benzylamino)-2-methyl-propanamide;2-(4-(exo-2- ...

Подробнее
14-11-2013 дата публикации

Thionating agent

Номер: US20130303767A1
Принадлежит: Vironova AB

A process for transforming a group >C═O (I) in a compound into a group >C═S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline P 2 S 5 .2 C 5 H 5 N as a thionating agent. A thionating agent which is crystalline P 2 S 5 .2 C 5 H 5 N.

Подробнее
14-11-2013 дата публикации

Method of producing biphenolic compound, novel biphenyl compound and synthesis method thereof, and pharmaceutical composition for treating parkinson's disease

Номер: US20130303788A1
Принадлежит: Tzu Chi Univ

A method of producing honokiol and analogues thereof, and novel intermediates prepared by virtue thereof are disclosed herein. A pharmaceutical composition for treating Parkinson's disease, which contains honokiol and/or the analogues thereof, is also disclosed herein.

Подробнее
21-11-2013 дата публикации

Liquid-crystalline compounds and liquid-crystalline media

Номер: US20130306908A1
Принадлежит: Merck Patent GmBH

The present invention relates to liquid-crystalline compounds containing an O-heterocyclic ring, three partially fluorinated benzene rings and a —CF 2 O— bridge between the rings. In addition, the invention relates to liquid-crystalline media prepared therewith and to liquid-crystal display devices (LC displays) containing these media.

Подробнее
21-11-2013 дата публикации

Maple tree-derived products and uses thereof

Номер: US20130310332A1

The present document describes a neutraceutical, cosmeceuticals, functional food, pharmaceutical, food ingredient, and non-food ingredient compositions comprising sugar maple extract, essential oil compositions comprising oil extracted from an Acer tree, sweetening compositions containing sugar extracted from maple tree leaves, food ingredients comprising maple tree extract, cosmetic composition comprising maple tree extracts, infusion compositions prepared from maple tree leaves, maple roots, maple wood, maple stems of leaves and samara, and stems/twigs as well as compounds isolated from sugar maple biomass and the methods of extracting the same.

Подробнее
21-11-2013 дата публикации

METHODS AND COMPOSITIONS FOR INHIBITION OF ATR AND FANCD2 ACTIVATION

Номер: US20130310448A1
Принадлежит: KAOHSIUNG MEDICAL UNIVERSITY

This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to Inhibit functions of ATR and FANCD2 on DNA replication, damage checkpoint, and repair; therefore, this composition can improve the cancer sensitivity and poor prognosis to DNA-damaging therapeutics. 1. A method for inhibiting a DNA damage response (DDR) , comprising steps of: providing an effective amount of a benzopyran-4-one derivative; and administering the effective amount of the benzopyran-4-one derivative to a subject in need thereof.4. A method as claimed in claim 1 , wherein the administering step further comprises a step of co-administering the benzopyran-4-one derivative and at least one of chemotherapeutic drug against a cancer disease to the subject in need thereof.5. A method as claimed in claim 4 , wherein the chemotherapeutic drugs include one selected from a group consisting of an alkylating agent claim 4 , an antimetabolic agent claim 4 , an antibiotic anti-cancer agent claim 4 , a Topoisomerase I claim 4 , a Topoisomerase II claim 4 , an anti-mitosis agent and a combination thereof.6. A method for inhibiting an ATR-mediated DNA damage checkpoint claim 4 , comprising a step of:providing an effective amount of a benzopyran-4-one derivative; andadministering the effective amount of the benzopyran-4-one derivative to a subject in need thereof.7. A method as claimed in claim 6 , wherein the administering step further comprises a step of co-administering the compound and at least one chemotherapeutic drugs against a cancer disease to the subject in need thereof.8. A method as claimed in claim 7 , wherein the chemotherapeutic drugs include one selected from a group consisting of an alkylating agent claim 7 , an antimetabolic agent claim 7 , an antibiotic anti-cancer agent claim 7 , a Topoisomerase I claim 7 , a ...

Подробнее
21-11-2013 дата публикации

Compound Separated from Monascus-Fermented Rice,The Preparation Method and Uses Thereof

Номер: US20130310450A1

The present invention discloses a compound separated from -fermented rice, the preparation method and uses thereof. Specifically, the present invention discloses a compound represented by the Formula I, or a pharmaceutically acceptable salt thereof, wherein, Ris selected from the group consisting of hydrogen, hydroxyl, Cstraight or branched alkoxyl, (II), (III) and (IV); Ris hydrogen or Calkyl; Ris selected from the group consisting of hydrogen, hydroxyl and Cstraight or branched alkoxyl. The present invention further discloses a pharmaceutical composition containing the compound. The compound of the present invention has HMG-CoA reductase inhibition effects. 3. A pharmaceutical composition claim 1 , which comprises the compound of or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable excipient.4. The pharmaceutical composition according to claim 3 , which is in the form of tablets claim 3 , granules claim 3 , capsules claim 3 , pills claim 3 , suppositories claim 3 , pulvis claim 3 , unguentums claim 3 , drops claim 3 , aerosols claim 3 , inhalable powders claim 3 , solutions claim 3 , suspensions claim 3 , buccal tablets claim 3 , lyophilized powders claim 3 , or emulsions.5. A method for preparing the compound of comprising the following steps:{'i': 'Monascus', '1) adding -fermented rice or an alcohol extract thereof to an organic solvent 1-10 times in volume, performing ultrasonic extraction at least one time, 10-60 minutes every time, combining the extracting solutions, concentrating under reduced pressure to obtain a concentrated solution;'}2) loading the concentrated solution on a silica gel column for separation, eluting in gradient manner with one or more eluent selected from the group consisting of petroleum ether, ethyl acetate and methanol; and3) subjecting the fraction containing the compound of Formula I or Formula II as obtained by elution in step 2) to the purification of silica gel column chromatography, sephadex ...

Подробнее
05-12-2013 дата публикации

Indanyloxyphenylcyclopropanecarboxylic acids

Номер: US20130324514A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of general formula I, wherein the groups R 1 , R 2 , R 3 , m and n are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Подробнее
05-12-2013 дата публикации

Process for preparing styrene derivatives

Номер: US20130324745A1
Принадлежит: Saltigo GmbH

A process is provided which allows the synthesis of a large number of styrene derivatives with formation of C—C bonds, with use being possible of economically advantageous substrates, readily available carbon nucleophiles, and both inexpensive and environmentally unproblematic catalyst systems, permitting reaction under mild conditions and a high compatibility with functional groups on the reactants involved.

Подробнее
12-12-2013 дата публикации

GLP-1 POTENTIATORS FROM HEDYCHIUM CORONARIUM AND THEIR APPLICATIONS

Номер: US20130331323A1
Принадлежит: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

A compound for controlling blood glucose level has a structure shown in Formula I: 5. A method for controlling blood glucose level claim 1 , comprising administering to a subject in need thereof the compound of .6. The method of claim 5 , further comprising administering to the subject a glucagon-like peptide-1 (GLP-1) receptor ligand to the subject.7. The method of claim 6 , wherein the GLP-1 receptor ligand is GLP-1 or exendin-4.8. The method of claim 6 , wherein the compound and the GLP-1 receptor ligand are administered together.10. The method of claim 9 , wherein the compound has a structure of 1A.11. The method of claim 9 , wherein the compound has a structure of 1B. 1. Technical Field of the InventionThe present invention relates to new uses of compounds, particularly a diterpenoid Galanal B, in the regulation of blood glucose levels.2. BackgroundGlucagon-like peptide-1 (GLP-1) analogues are a new class of hypoglycemic agents. GLP-1 is a member of the incretin family, which comprises gastrointestinal hormones that help control blood glucose levels after meals. GLP-1 exerts its functions by specific binding to GLP-1 receptor. GLP-1 receptor (GLP-1R) is widely distributed. In addition to pancreatic tissue, GLP-1 receptor is also distributed in the brain, lung, heart, kidney, etc. The wide distribution of this receptor contributes to the wide range of its functions.GLP-1 bind specifically to the GLP-1 receptor on the pancreatic beta cells. Activation of GLP-1R leads to stimulation of the adenylyl cyclase pathway, which eventually leads to increased insulin synthesis and release. In addition to the increased insulin synthesis and release, GLP-1 binding to its receptor also inhibits the production of glucagon and maintains constant levels of blood glucose after meals. Furthermore, GLP-1 also has a neuron regulatory function, which can delay gastric emptying and reduce appetite. At the same time, the hypoglycemic effect of GLP-1 is self-limiting and will not result ...

Подробнее
26-12-2013 дата публикации

QUINOLINONE DERIVATIVES

Номер: US20130345212A1
Принадлежит: GlaxoSmithKline LLC

The present invention relates to compounds of the formula (I), 2. A compound of formula (I) or a salt thereof according to wherein Rrepresents-5 membered heteroaryl optionally substituted by a group independently selected from —CH claim 1 , —OCH claim 1 , —OH claim 1 , —CHOH claim 1 , —CF claim 1 , —OCF claim 1 , —CN claim 1 , —COH claim 1 , —CHCOH claim 1 , —CONH claim 1 , —NHand halogen.3. A compound of formula (I) or a salt thereof according to wherein Rrepresents a 5-membered heteroaryl optionally substituted with 1 or more groups selected from methyl claim 1 , chloro claim 1 , bromo claim 1 , COH and methoxy.8. A compound of formula (I) or a salt thereof according to wherein the salt is a pharmaceutically acceptable salt.913-. (canceled)14. A method of treating a disease or a condition mediated by AMPK activation claim 8 , which method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to provided the compound is not 7-chloro-4-hydroxy-3-(3-methyl-1H-pyrazol-1-yl)-6-(4-(pyrrolidin-1-yl)phenyl)quinolin-2(1H)-one claim 8 , 7-chloro-4-hydroxy-3-(2-methylthiazol-4-yl)-6-(4-(piperidin-1-yl)phenyl)quinolin-2(1H)-one claim 8 , 7-chloro-6-(4-(dimethylamino)phenyl)-4-hydroxy-3-(5-methylisoxazol-3-yl)quinolin-2(1H)-one claim 8 , 7-chloro-6-(4-(dimethylamino)phenyl)-3-(2 claim 8 ,5-dimethylthiazol-4-yl)-4-hydroxyquinolin-2(1H)-one or 7-chloro-4-hydroxy-6-(3′-methoxy-[1 claim 8 ,1′-biphenyl]-4-yl)-3-(1H-pyrazol-1-yl)quinolin-2(1H)-one.15. A method of treating type 1 diabetes claim 8 , type 2 diabetes claim 8 , metabolic syndrome claim 8 , atherosclerosis claim 8 , dyslipidaemia claim 8 , mitochondrial disorders claim 8 , sarcopenia claim 8 , obesity claim 8 , hypertension claim 8 , cerebral ischemia claim 8 , cognitive defect claim 8 , Alzheimer's disease claim 8 , Parkinson's disease claim 8 , Huntington's disease claim 8 , schizophrenia claim 8 , ...

Подробнее
26-12-2013 дата публикации

PROCESS AND INTERMEDIATE COMPOUNDS USEFUL IN THE PREPARATION OF STATINS

Номер: US20130345429A1
Принадлежит:

There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein Rrepresents an alkyl group, such as a Calkyl group, and preferably an isopropyl group; Rrepresents an aryl group, preferably a 4-fluorophenyl group; Rrepresents hydrogen, a protecting group or an alkyl group, such as a Calkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SORgroup where Ris an alkyl group, such as a Calkyl group, and preferably a methyl group. 17-. (canceled)9. The process of wherein Y is Cl or Br.11. The process of claim 10 , wherein Ris an alkyl group and/or Ris an alkanoyl group.12. The process of claim 11 , wherein Ris a Calkyl group and/or Ris a Calkanoyl group.13. The process of claim 12 , wherein Ris a —C(O)CH(Me)CHCHor —C(O)C(Me)CHCHgroup14. The process of claim 10 , wherein Ris an alkanoyl group.15. The process of claim 14 , wherein Ris a Calkanoyl group16. The process of claim 14 , wherein Ris a —C(O)CH(Me)CHCHor a —C(O)C(Me)CHCHgroup.17. The process of claim 10 , wherein Ris a substituted or unsubstituted aryl group and/or Ris a substituted or unsubstituted alkyl group.18. The process of claim 17 , wherein Ris a 4-fluorophenyl group and/or Ris a cyclopropyl group.19. The process of claim 10 , wherein Ris a substituted or unsubstituted aryl group and/or Ris a substituted or unsubstituted alkyl group.20. The process of claim 19 , wherein Ris a 4-fluorophenyl group and/or Ris an isopropyl group.21. The process of claim 10 , wherein Ris a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; Ris a substituted or unsubstituted aryl group; and/or Ris a substituted or unsubstituted aryl group.22. The process of claim 21 , wherein Ris a methyltetrazoyl group; Ris a 4-fluorophenyl group; and/or Ris a 4-fluorophenyl group.23. ...

Подробнее
02-01-2014 дата публикации

SMALL MOLECULE ANTAGONISTS OF THE APELIN RECEPTOR FOR THE TREATMENT OF DISEASE

Номер: US20140005181A1

The present disclosure relates to compounds and methods for treating a disease mediated by apelin. 3. The method of claim 2 , wherein —Y—Y— is —CH— claim 2 , —CH—N(CH—CH)— claim 2 , —CH—S— claim 2 , or —CH—S(O)—.4. The method of claim 2 , wherein B is selected from the group consisting of phenyl claim 2 , pyrimidinyl claim 2 , morpholinyl claim 2 , thiomorpholinyl claim 2 , and piperazinyl claim 2 , wherein each phenyl claim 2 , pyrimidinyl claim 2 , morpholinyl claim 2 , thiomorpholinyl claim 2 , and piperazinyl is optionally substituted with from one to three R.5. The method of claim 2 , wherein each Ris independently selected from the group consisting of halogen claim 2 , —NO claim 2 , —CN claim 2 , —S(O)—N(CH) claim 2 , —S(O)-heterocycloalkyl claim 2 , alkyl claim 2 , alkoxy claim 2 , haloalkyl claim 2 , haloalkoxy claim 2 , phenyl claim 2 , and heteroaryl.9. The method of claim 8 , wherein the disease is selected from the group consisting of neoplasia claim 8 , cardiovascular disease claim 8 , peripheral vascular disease claim 8 , hypertension claim 8 , preeclampsia syndrome claim 8 , abnormal angiogenesis claim 8 , diabetes claim 8 , ocular degeneration claim 8 , idiopathic pulmonary fibrosis claim 8 , would healing claim 8 , chronic obstructive pulmonary disease claim 8 , inflammatory disease such as arthritis claim 8 , and inflammatory bowel disease claim 8 , cardiovascular disease claim 8 , avascular or ischemic insult claim 8 , myocardial infarction claim 8 , stroke claim 8 , vaculitis claim 8 , systemic or vascular sclerosis claim 8 , gangrene claim 8 , congelation claim 8 , alopecia claim 8 , eczema claim 8 , ulcers claim 8 , lymphedema claim 8 , vascular hyperplasia claim 8 , hemangioma claim 8 , diabetic induce retinopathy claim 8 , macular degenerative disease claim 8 , psoriasis claim 8 , or endometriosis.10. The method of claim 8 , wherein the disease is ocular degeneration.11. The method of claim 8 , wherein the disease is caused by abnormal ...

Подробнее
02-01-2014 дата публикации

NOVEL HERBICIDES

Номер: US20140005389A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides. 2. A compound according to claim 1 , wherein Ris halogen claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-Calkenyl or C-Calkynyl.3. A compound according to claim 1 , wherein Ris hydrogen claim 1 , which means that r is 0 claim 1 , or Ris halogen or C-Calkyl.4. A compound according to claim 1 , wherein R claim 1 , R claim 1 , Rand R claim 1 , independently of each other claim 1 , are hydrogen claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-CalkoxyC-Calkyl claim 1 , C-CalkylthioC-Calkyl claim 1 , C-CalkylsulfinylC-Calkyl claim 1 , C-CalkylsulfonylC-Calkyl; C-Ccycloalkyl or C-Ccycloalkyl substituted by C- or Calkyl or C- or Chaloalkyl and in which a methylene group is optionally replaced by an oxygen or sulfur atom or a sulfinyl or sulfonyl group; C-CcycloalkylC-Calkyl or C-CcycloalkylC-Calkyl substituted by C-Calkyl or C- or Chaloalkyl and in which a methylene group is optionally replaced by an oxygen or sulfur atom or a sulfinyl or sulfonyl group.5. A compound according to claim 1 , wherein R claim 1 , R claim 1 , Rand R claim 1 , independently of each other claim 1 , are hydrogen claim 1 , C-Calkyl claim 1 , C-Chaloalkyl or C-Calkoxy-C-Calkyl.6. A compound according to claim 1 , wherein Y is O claim 1 , S or C═O.7. A compound according to claim 1 , wherein{'sup': 1', '3', '4', '5', '6', '7, 'sub': 1', '4', '1', '2, 'Ris C-Calkyl; Ris hydrogen, which means that r is 0; R, R, Rand R, independently of each other, are C-Calkyl; and Y is O.'} This application is a divisional of application Ser. No. 12/519,015, which is a 371 of International Application No. PCT/EP2007/010848 filed Dec. 12, 2007, which claims priority to GB 0624961.9 filed Dec. 14, 2006, and GB 0705044.6 filed on Mar. 15, 2007, the contents of which are incorporated herein by reference.The present invention relates to novel, herbicidally active cyclic diones, and derivatives thereof, to ...

Подробнее
09-01-2014 дата публикации

Crystalline form of benzylbenzene sglt2 inhibitor

Номер: US20140011754A9
Принадлежит: Theracos Inc

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Подробнее
09-01-2014 дата публикации

CHEMICAL COMPOUNDS

Номер: US20140011845A1
Принадлежит: SYNGENTA PARTICIPATIONS AG

Disclosed are cyclic dione derivatives represented by formula (I), wherein the substituents are as defined in the description. The preparation method, intermediate and use thereof are also provided. 2. Compounds according to the formula I of wherein{'sub': '1-4', 'X, Y and Z independently of each other are Calkyl or halogen;'}p and q, independently of each other, are 1 or 2;G is hydrogen or a latentiating group;{'sup': 1', '1', '1, 'sub': '1-6', 'D is O, NRor NOR, wherein Ris hydrogen or Calkyl;'}{'sup': 5', '6', '7, 'sub': 1', '6, 'R, Rand R, independently of each other, are hydrogen, halogen or C-Calkyl;'}{'sub': 3-8', '1-4', '1-4', '1-4', '1-2', '3-6', '1-4', '1-6', '1-6', '3-7', '1-6', '1-6', '1-6', '1-6, 'sup': 03', '03, 'Q is a saturated or mono-unsaturated Cheterocyclyl containing at least one heteroatom selected from O, N and S, which heterocyclyl is unsubstituted or substituted at a carbon, S or N atom by a residue of formula ═O, ═N—R, Calkyl, Chaloalkyl, CalkoxyCalkyl, Ccycloalkyl, Calkoxy, where Ris Calkyl, Chaloalkyl, Ccycloalkyl, Calkoxy, Chaloalkoxy, Chaloalkylcarbonyl, Calkoxycarbonyl or cyano; and'}m is 0 or 1.3. Compounds according to the formula I of or wherein{'sub': 1-4', '1-4, 'X is a Calkyl, Y and Z independently of each other are Calkyl or halogen;'}p and q, independently of each other, are 1 or 2;G is hydrogen or a latentiating group;{'sup': 1', '1', '1, 'sub': '1-6', 'D is O, NRor NOR, wherein Ris hydrogen or Calkyl;'}{'sup': 5', '6', '7, 'sub': 1', '6, 'R, Rand R, independently of each other, are hydrogen, halogen or C-Calkyl;'}{'sub': 3-8', '1-4', '1-4', '1-6', '1-6', '3-7', '1-6', '1-6', '1-6', '1-6, 'sup': 03', '03, 'Q is a saturated or mono-unsaturated Cheterocyclyl containing at least one heteroatom selected from O, N and S, which heterocyclyl is unsubstituted or substituted at a carbon, S or N atom by a residue of formula ═O, ═N—R, Calkyl or Calkoxy, where Ris Calkyl, Chaloalkyl, Ccycloalkyl, Calkoxy, Chaloalkoxy, Chaloalkylcarbonyl, ...

Подробнее
09-01-2014 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20140012020A1
Принадлежит:

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. This Divisional application claims the benefit of U.S. Ser. No. 13/361,541 filed Jan. 30, 2012, now allowed, which in turn claims the benefit of U.S. Provisional Application Ser. No. 61/467,602 filed Mar. 25, 2011 and U.S. Provisional Application Ser. No. 61/440,086 filed Feb. 7, 2011.The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.HCV is a major human pathogen, infecting an estimated 170 million persons worldwide—roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma.The current standard of care for HCV, which employs a combination of pegylated-interferon and ribavirin, has a non-optimal success rate in achieving sustained viral response and causes numerous side effects. Thus, there is a clear and long-felt need to develop effective therapies to address this undermet medical need.HCV is a positive-stranded RNA virus. Based on a comparison of the deduced amino acid sequence and the extensive similarity in the 5′ untranslated region, HCV has been classified as a separate genus in the Flaviviridae family. All members of the Flaviviridae family have enveloped virions that contain a positive stranded RNA genome encoding all known virus-specific proteins via translation of a single, uninterrupted, open reading frame.Considerable heterogeneity is found within the nucleotide and encoded ...

Подробнее
16-01-2014 дата публикации

METHOD FOR MANUFACTURING NEURAMINIC ACID DERIVATIVES

Номер: US20140018417A1
Принадлежит: Daiichi Sankyo Company, Limited

A method for manufacturing a compound represented by the formula (13): 2. The manufacturing method according to claim 1 , wherein Ris a methyl group.4. The compound according to claim 3 , wherein Ris a methyl group.6. The manufacturing method according to claim 5 , wherein Ris a 1-heptyl group claim 5 , Ris a methyl group and Ris a methyl group.8. The manufacturing method according to claim 7 , wherein Ris a 1-heptyl group claim 7 , Ris a methyl group claim 7 , Ris a methyl group and X is Cl.11. A composition comprising the compound represented by the formula (I) and up to 10 wt. % of the compound represented by the formula (II) claim 10 , or a pharmacologically acceptable salt thereof according to claim 10 , wherein the chemical purity of the compound represented by the formula (I) is 99 wt. % or higher.12. A composition comprising the compound represented by the formula (I) and up to 10 wt. % of the compound represented by the formula (II) claim 10 , or a pharmacologically acceptable salt thereof according to claim 10 , wherein the chemical purity of the compound represented by the formula (I) is 99.5 wt. % or higher.13. A composition comprising the compound represented by the formula (I) and up to 10 wt. % of the compound represented by the formula (II) claim 10 , according to claim 10 , wherein Ris a 1-heptyl group and Ris a methyl group.15. A composition comprising the compound represented by the formula (I) and the compound represented by the formula (II) claim 14 , or a pharmacologically acceptable salt thereof according to claim 14 , containing 0.3 wt. % or less of the compound represented by the formula (VIII).16. A composition comprising the compound represented by the formula (I) and the compound represented by the formula (II) claim 14 , or a pharmacologically acceptable salt thereof according to claim 14 , containing 0.1 wt. % or less of the compound represented by the formula (VIII).17. A composition comprising the compound represented by the formula ( ...

Подробнее
23-01-2014 дата публикации

SULFONAMIDE DERIVATIVE AND USE THEREOF

Номер: US20140024650A1
Принадлежит: Takeda Pharmaceutical Company Limited

Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): 2. The compound according to claim 1 , wherein ring A is{'sub': '3-6', 'optionally further substituted Ccycloalkane,'}an optionally further substituted tetrahydrofuran ring,an optionally further substituted tetrahydropyran ring,an optionally further substituted piperidine ring,an optionally further substituted tetrahydrothiopyran ring oran optionally further substituted 8-oxabicyclo[3.2.1]octane ring,or a salt thereof.3. The compound according to claim 1 , wherein the substituent(s) on the ring A is(are) selected from(1) 1 to 3 halogen atoms,{'sub': '1-6', '(2) a Calkyl group optionally substituted by one phenyl group,'}{'sub': '1-6', '(3) a carbamoyl group substituted by a Calkyl group,'}{'sub': '1-6', '(4) a Calkyl-carbonyl group,'}{'sub': '1-6', '(5) a Calkoxy-carbonyl group,'}(6) an oxo group,(7) a hydroxyl group and{'sub': '1-6', '(8) a Calkylsulfonyl group,'}or a salt thereof.5. The compound according to claim 1 , wherein ring B is a benzene ring claim 1 , or a salt thereof.6. The compound according to claim 1 , wherein the substituent on the ring B is selected from(1) a halogen atom;(2) a cyano group;{'sub': '1-6', '(3) a Calkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a cyano group;'}{'sub': '1-6', '(4) a hydroxyl group optionally substituted by a Calkyl group optionally substituted by 1 to 3 halogen atoms or a phenyl group (including alkoxy);'}{'sub': 1-6', '1-6, '(5) an amino group optionally substituted by 1 or 2 substituents selected from a Calkyl group, a Calkyl-carbonyl and a phenyl group;'}{'sub': '3-6', '(6) a Ccycloalkyl group;'}(7) a tricyclo[3.3.1.1.3.7]decyl group;(8) phenyl optionally substituted by 1 to 3 substituents selected ...

Подробнее
06-02-2014 дата публикации

METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES

Номер: US20140039048A1
Принадлежит: Acucela Inc.

Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions. 2. (canceled)3. (canceled)4. The method of claim 1 , wherein n is 0 claim 1 , 1 claim 1 , or 2.5. (canceled)6. (canceled)7. The method of claim 4 , wherein X is —C(R)—O—.8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. The method of claim 7 , wherein Y is substituted or unsubstituted carbocyclyl claim 7 , or substituted or unsubstituted C-Calkyl.13. The method of claim 12 , wherein Y is substituted or unsubstituted carbocyclyl.14. The method of claim 12 , wherein Y is substituted or unsubstituted C-Calkyl.15. The method of claim 13 , wherein the substituted or unsubstituted carbocyclyl is a substituted or unsubstituted 4- claim 13 , 5- claim 13 , 6- claim 13 , or 7-membered ring.16. The method of claim 14 , wherein the substituted or unsubstituted C-Calkyl is a substituted or unsubstituted C-Calkyl.17. The method of claim 16 , wherein the substituted C-Calkyl is substituted with an C-Calkoxy group.18. The method of claim 18 , wherein the substituted C-Calkyl is —CHCHCHOCH.19. The method of claim 15 , wherein the substituted or unsubstituted carbocyclyl is a 6-membered ring.20. The method of claim 19 , wherein the substituted or unsubstituted 6-membered ring is a substituted or unsubstituted cyclohexyl.21. (canceled)22. The method of claim 1 , wherein Ris hydrogen and Ris hydroxyl.23. The method of claim 1 , wherein Rand Rform an oxo.24. The method of claim 1 , wherein Ris hydrogen.25. The method of claim 1 , wherein Ris methyl.26. (canceled)27. ( ...

Подробнее
06-02-2014 дата публикации

CHEMICAL COMPOUNDS

Номер: US20140039207A1
Принадлежит:

The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. 115-. (canceled) The human immunodeficiency virus (“HIV”) is the causative agent for acquired immunodeficiency syndrome (“AIDS”), a disease characterized by the destruction of the immune system, particularly of CD4 T-cells, with attendant susceptibility to opportunistic infections, and its precursor AIDS-related complex (“ARC”), a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss. HIV is a retrovirus; the conversion of its RNA to DNA is accomplished through the action of the enzyme reverse transcriptase. Compounds that inhibit the function of reverse transcriptase inhibit replication of HIV in infected cells. Such compounds are useful in the prevention or treatment of HIV infection in humans.A required step in HIV replication in human T-cells is the insertion by virally-encoded integrase of proviral DNA into the host cell genome. Integration is believed to be mediated by integrase in a process involving assembly of a stable nucleoprotein complex with viral DNA sequences, cleavage of two nucleotides from the 3′ termini of the linear proviral DNA and covalent joining of the recessed 3′ OH termini of the proviral DNA at a staggered cut made at the host target site. The repair synthesis of the resultant gap may be accomplished by cellular enzymes.There is continued need to find new therapeutic agents to treat human diseases. HIV integrase is an attractive target for the discovery of new therapeutics due to its important role in viral infections, particularly HIV infections. Integrase inhibitors are disclosed in WO2006/116724. The compounds of the present invention are designed to deliver active therapeutic agents.The present invention features ...

Подробнее
27-02-2014 дата публикации

TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZYLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISUBSTITUTED PYRAN DERIVATIVES

Номер: US20140058120A1
Автор: DUTTA Aloke K.
Принадлежит: WAYNE STATE UNIVERSITY

Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants. 124-. (canceled) This application is a continuation of U.S. Ser. No. 12/836,878, filed Jul. 15, 2010, issued as U.S. Pat. No. 8,519,159 on Aug. 27, 2013, which is a continuation of U.S. Ser. No. 10/599,892, filed Oct. 12, 2006, issued as U.S. Pat. No. 7,915,433 on Mar. 29, 2011, which is a national phase of PCT/US05/12748, filed Apr. 15, 2005, which claims the benefit of U.S. provisional application Ser. No. 60/563,189, filed Apr. 16, 2004, the entire disclosures of each of which are hereby incorporated by reference herein.1. Field of the InventionThe invention pertains to pharmacologically active 3,6-disubstituted pyran compounds and similar compounds having additional substitution on the pyran ring. The compounds show high activity at monoamine transporters, and thus can be used to alter reuptake of monoamines in treatment of numerous diseases in mammalian species for which alteration of the monoamine transport system is indicated.2. Background ArtThe monoamine transporters terminate the action of released biogenic amines such as dopamine (DA), norepinephrine (NE) and serotonin (5-HT) in the central nervous system (CNS) and are known as dopamine transporter (DAT), norepinephrine transporter (NET) and serotonin transporter (SERT), respectively.These transporters play a vital role in maintaining the extracellular concentration of biogenic amine neurotransmitters.Drugs binding to the DAT are typically regarded as stimulants. Cocaine- and amphetamine-related compounds are known to produce their action by binding to both DAT and SERT with cocaine acting as a blocker and amphetamine as a substrate.On the other hand, drugs binding to the SERT and NET are known to produce, among other effects, potent antidepressant activity.Major depression disorder is a significant health problem, and behind cardiovascular ...

Подробнее
06-03-2014 дата публикации

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Номер: US20140066621A1
Принадлежит:

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. 112-. (canceled)15. A compound or a therapeutically acceptable salt thereof , wherein the compound is selected from the group consisting of:4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(2,3-difluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide;2-(4-amino-3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide;4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(2,5-dichlorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide;N-(4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrophenylsulfonyl)-2-(3-chlorophenoxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzamide;4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(3-fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide;2-(2-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide;2-(2-chloro-4-fluorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide;4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(2-fluorophenoxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide;4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(2-fluorophenoxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)benzamide;2-(3-chlorophenoxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1- ...

Подробнее
13-03-2014 дата публикации

Compounds for use in the treatment of filariasis

Номер: US20140073688A1

A compound for use in a therapeutic treatment of filariasis or a prophylactic treatment of filariasis of the general formula (1) or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of the general formula (1), a nematicidal composition comprising as an active ingredient a compound according to the general formula (1), and a method for treating filariasis.

Подробнее
13-03-2014 дата публикации

PROCESS FOR THE PREPARATION OF ZANAMIVIR

Номер: US20140073804A1
Принадлежит:

The present invention provides a process for preparing 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-enonic acid Formula (I), which process comprises reducing compound of Formula (IV) by Lindlar catalyst in presence of hydrogen to obtain compound of Formula (V). reacting compound of Formula (V) with pyrazole-1H-carboxamidine or its suitable salt to obtain compound of Formula (VIII). hydrolyzing the compound of Formula (VIII) to give compound of Formula (I). The present invention also provides compounds of formula (VIII) which may be used in the synthesis of zanamivir. The present invention also provides process for preparing compound of formula (VIII) and process involving the use of Formula (VIII), including in the synthesis of zanamivir. 2. The process for the preparation of compound of Formula (I) as claimed in claim 1 , wherein the suitable solvent of step (a) is selected from (C-C) alcohols claim 1 , ethers claim 1 , chlorinated solvents claim 1 , nitriles claim 1 , ketones claim 1 , and aprotic polar solvents or a mixture thereof.3. The process for the preparation of compound of Formula (I) as claimed in claim 1 , wherein the suitable salt of an acid of step (b) is selected from hydrochloride claim 1 , hydrobromide claim 1 , acetate claim 1 , sulfate and benzene sulfonate.4. The process as claimed in claim 3 , wherein the salt is hydrochloride salt.5. The process for the preparation of compound of Formula (I) as claimed in claim 1 , wherein the suitable solvent of step (b) is selected from water claim 1 , (C-C) alcohols claim 1 , ethers claim 1 , esters claim 1 , chlorinated solvents claim 1 , nitriles claim 1 , ketones claim 1 , and aprotic polar solvents or a mixture thereof.6. The process for the preparation of compound of Formula (I) as claimed in claim 1 , wherein the suitable solvent of step (c) is selected from ethers claim 1 , chlorinated solvents claim 1 , nitriles claim 1 , and aprotic polar solvents ...

Подробнее
27-03-2014 дата публикации

Process

Номер: US20140088064A1
Принадлежит: IRON THERAPEUTICS HOLDINGS AG

The invention provides a method of forming an iron hydroxypyrone compound comprising reacting a hydroxypyrone with a non-carboxylate iron salt in an aqueous solution, and precipitating the iron hydroxypyrone compound from the aqueous solution having a pH of greater than 7.

Подробнее
27-03-2014 дата публикации

NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS

Номер: US20140088079A1
Принадлежит: GREEN CROSS CORPORATION

The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound. 5. The compound of , wherein said ring A is a benzene , indane , indene , dihydrobenzofuran , dihydroisobenzofuran , benzofuran , dihydrobenzothiophene , benzothiophene , tetrahydronaphthalene , dihydronaphthalene , chroman , chromene , isochroman , isochromene , benzodioxole , benzodioxane , benzooxazine , tetrahydroquinoline , tetrahydroquinoxaline , tetrahydroisoquinoline , indazole , indole , indoline , benzoimidazole , benzooxazole , benzothiazole , benzotriazole , quinazoline , quinoxaline , cinnoline , phthalazine , or benzotriazine ring , which is optionally substituted with a substituent as defined in .6. The compound of , wherein said ring B is a quinoline , quinoxaline , 3 ,4-dihydro-2H-benzo[b][1 ,4]dioxepine , 2 ,3-dihydrobenzo[b]thiophene , indazole , indole , 2 ,3-dihydrobenzo[b][1 ,4]dioxine , benzodioxole , indane , tetrahydronaphthalene , 3 ,4-dihydro-2H-thiochromene , dihydrobenzofuran , benzo[d][1 ,3]oxathiole , tetrahydroquinoline , or 3 ,4-dihydro-2H-benzo[b][1 ,4]oxazine ring , which is optionally substituted with a substituent as defined in .7. The compound of claim 1 , which is selected from the group consisting of:(1) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-methoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;(2) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4-ethoxybenzyl)-2,3-dihydro-1H-inden-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;(3) (2S,3R,4R,5S,6R)-2-(7-bromo-6-(4- ...

Подробнее
27-03-2014 дата публикации

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Номер: US20140088106A1
Принадлежит: AbbVie Inc.

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. 3. The compound of or , wherein{'sup': 1', '2, 'Ais C(A); and'}{'sup': '2', 'Ais H.'}4. The compound of or , wherein{'sup': 1', '2, 'Ais C(A) or N;'}{'sup': '2', 'Ais H; and'}{'sup': 1', '1, 'Bis NHR.'}5. The compound of or , wherein{'sup': 1', '2, 'Ais C(A) or N;'}{'sup': '2', 'Ais H;'}{'sup': 1', '1, 'Bis NHR; and'}{'sup': '1', 'Dis H.'}6. The compound of or , wherein{'sup': 1', '2, 'Ais C(A) or N;'}{'sup': '2', 'Ais H;'}{'sup': 1', '1, 'Bis NHR;'}{'sup': '1', 'Dis H; and'}{'sup': '1', 'Eis H.'}7. The compound of or , wherein{'sup': 1', '2, 'Ais C(A) or N;'}{'sup': '2', 'Ais H;'}{'sup': 1', '1, 'Bis NHR;'}{'sup': '1', 'Dis H;'}{'sup': '1', 'Eis H; and'}{'sup': '1', 'sub': '2', 'Yis NO.'}8. A compound of claim 1 , wherein the compound is chosen from:4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-((dimethylamino)methyl)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-(methylamino)phenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-2-((2-methyl-1H-indol-5-yl)oxy)-N-((4-((1-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide;4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-2-((2-methyl-1H-indol-5-yl)oxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(2-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(3-chlorophenoxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide;4-(4 ...

Подробнее
27-03-2014 дата публикации

ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

Номер: US20140088158A1
Принадлежит: SANOFI

The present invention relates to compounds of the formula I, 2. The compound according to claim 1 , wherein ring A is a 3-membered to 8-membered monocyclic ring which comprises 0 or 1 hetero ring members chosen from the series consisting of O claim 1 , S claim 1 , S(O) and S(O) claim 1 , and which is saturated claim 1 , wherein ring A is optionally substituted on ring carbon atoms by one or more identical or different substituents chosen from the series consisting of halogen claim 1 , R claim 1 , R claim 1 , (C-C)-alkenyl claim 1 , HO— claim 1 , R—O— claim 1 , phenyl-(C-C)-alkyl-O— claim 1 , R—C(O)—O— claim 1 , R—S(O)—O— claim 1 , HO—C(O)— claim 1 , R—O—C(O)— claim 1 , HN—C(O)— claim 1 , R—NH—C(O)— claim 1 , R—N(R)—C(O)— and oxo;or a stereoisomeric form thereof or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.3. The compound according to claim 1 , wherein ring A is a cyclohexane ring or cycloheptane ring claim 1 , each of which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen claim 1 , R claim 1 , R claim 1 , (C-C)-alkenyl claim 1 , HO— claim 1 , R—O— claim 1 , phenyl-(C-C)-alkyl-O— claim 1 , R—C(O)—O— claim 1 , R—S(O)—O— claim 1 , HO—C(O)— claim 1 , R—O—C(O)— claim 1 , HN—C(O)— claim 1 , R—NH—C(O)— claim 1 , R—N(R)—C(O)— and oxo;or a stereoisomeric form thereof or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.4. The compound according to claim 1 , wherein{'sup': 12', '13', '15, 'Y is chosen from the series consisting of C(R)═C(R) and C(R)═N; and'}{'sup': '16', 'Z is C(R);'}or a stereoisomeric form thereof or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.5. The compound according to claim 1 , wherein{'sup': 21', '1', '13', '14', '13', '14, 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', 'm', '1', '4, 'Ris ...

Подробнее
27-03-2014 дата публикации

METHOD OF EXTRACTING PHENOLIC FRACTIONS OF EXTRA VIRGIN OLIVE OIL

Номер: US20140088299A1
Принадлежит: PhytoChem Pharmaceuticals, Inc.

The present invention relates to isolating phenolics from extra virgin olive oil (EVOO) having a low triglyceride and non-polar content. The method includes an ethanol/water extraction with a heptane wash 1. A method for isolating phenolics from EVOO , wherein the isolated phenolics have a low triglyceride and non-polar content comprising:a) selecting a desired quantity of EVOO for extraction;b) extracting the EVOO a plurality of times with an ethanol/water solution;c) isolating the ethanol/water solution after each extraction;d) rinsing the ethanol/water solution with a heptane solution;e) isolate the ethanol/water solution from the heptane; andf) evaporate the ethanol/water solution to remove the phenolics from the solution.2. A method according to wherein the plurality isolated solutions of step c) are combined before step d).3. A method according to wherein the evaporation is carried out by a method selected from the list comprising rotary evaporation and speed vacuum evaporation.4. A method according to wherein the ethanol comprises about 50 to 90 percent of the ethanol/water solution.5. A method according to wherein the ethanol comprises about 80 percent of the ethanol/water solution.6. A method according to which further comprises the addition of further ethanol/water solution to the isolated solution in step e) during the evaporation process.7. A phenolic extract of EVOO manufactured by the method of .8. A polar phenolic extract of EVOO comprising EVOO that has been extracted with an ethanol/water solution than then has been washed with a solution of heptane. This application claims priority of U.S. provisional application No. 61/448,265 filed on Mar. 2, 2011 and included herein in its entirety by reference.A portion of the disclosure of this patent contains material that is subject to copyright protection. The copyright owner has no objection to the reproduction by anyone of the patent document or the patent disclosure as it appears in the Patent and ...

Подробнее
03-04-2014 дата публикации

Chemically Programmed Vaccination

Номер: US20140093518A1
Автор: Barbas, III Carlos F.
Принадлежит: The Scripps Research Institute

Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound. 20. A method of extending the half life of a therapeutic drug in a patient in need thereof claim 1 , the method comprising the step of administering the compound of having formula I to the patient in need thereof.22. The method of claim 21 , wherein HIV-1 infection is inhibited by blocking the CCR5 and/or CXCR4 receptors.23. A method of generating covalent polyclonal antibodies claim 21 , the method comprising the steps of:preimmunizing a subject with an immunizing effective amount of a carrier protein-hapten complex; andadministering a targeting compound to the subject, thereby generating a covalent polyclonal antibody response to a target antigen.24. The method of claim 23 , wherein the target antigen is a tumor antigen claim 23 , a self antigen claim 23 , a toxin claim 23 , a cancer antigen claim 23 , a bacterial antigen claim 23 , a viral antigen claim 23 , or an integrin.25. The method of claim 24 , wherein the integrin is αvβ3 or αvβ5.26. The method of claim 24 , wherein the cancer is melanoma claim 24 , colon cancer claim 24 , glioma claim 24 , ovarian cancer claim 24 , cervical cancer claim 24 , breast cancer claim 24 , prostate cancer claim 24 , lung cancer claim 24 , a hematopoietic cancer claim 24 , or head and neck cancer.27. The method of claim 23 , wherein the carrier protein is selected from KLH claim 23 , BSA and ovalbumin.28. The method of claim 23 , wherein the subject is a human.29. The method of claim 24 , wherein the target antigen is CCR5.31. The method of claim 24 , wherein the targeting compound has formula I of .32. An enriched population of covalent polyclonal antibodies.33. A method of treating or preventing a disease or condition in a subject wherein the disease or condition involves cells claim 24 , tissue or fluid that ...

Подробнее
03-04-2014 дата публикации

CATALYTIC CONVERSION OF CELLULOSE TO LIQUID HYDROCARBON FUELS BY PROGRESSIVE REMOVAL OF OXYGEN TO FACILITATE SEPARATION PROCESSES AND ACHIEVE HIGH SELECTIVITIES

Номер: US20140094618A1
Принадлежит: WISCONSIN ALUMNI RESEARCH FOUNDATION

Described is a method to make liquid chemicals. The method includes deconstructing cellulose to yield a product mixture comprising levulinic acid and formic acid, converting the levulinic acid to γ-valerolactone, and converting the γ-valerolactone to pentanoic acid. Alternatively, the γ-valerolactone can be converted to a mixture of n-butenes. The pentanoic acid can be decarboxylated yield 1-butene or ketonized to yield 5-nonanone. The 5-nonanone can be hydrodeoxygenated to yield nonane, or 5-nonanone can be reduced to yield 5-nonanol. The 5-nonanol can be dehydrated to yield nonene, which can be dimerized to yield a mixture of Cand Colefins, which can be hydrogenated to yield a mixture of alkanes. 1. A method for converting glucose to γ-valerolactone , the method comprising:(a) hydrolyzing glucose derived from any source in an aqueous, acid-catalyzed reaction to yield a product mixture comprising levulinic acid and formic acid; then{'sub': 2', '2, '(b) converting at least a portion of the formic acid present in the product mixture to Hand COwithout separating the levulinic acid and formic acid present in the product mixture; and'}{'sub': '2', '(c) reducing at least a portion of the levulinic acid present in the product mixture to γ-valerolactone using the Hproduced in step (b).'}2. The method of claim 1 , wherein step (a) comprises hydrolyzing the glucose by reacting it with an acid.3. The method of claim 2 , wherein step (a) comprises hydrolyzing the glucose by reacting it with a mineral acid selected from the group consisting of sulfuric acid claim 2 , hydrochloric acid claim 2 , nitric acid claim 2 , phosphoric acid claim 2 , boric acid claim 2 , hydrofluoric acid claim 2 , hydrobromic acid claim 2 , oxalic acid claim 2 , acetic acid claim 2 , acetic anhydride claim 2 , and combinations thereof.4. The method of claim 1 , wherein step (b) comprises converting the converting the formic acid present in the product mixture to Hand COby contacting the product mixture ...

Подробнее
10-04-2014 дата публикации

Guanidine compound

Номер: US20140100210A1
Принадлежит: Astellas Pharma Inc

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Подробнее
06-01-2022 дата публикации

PREPARATION OF 2-SUBSTITUTED 4-METHYL-TETRAHYDROPYRANS FROM 2-SUBSTITUTED 4-HYDROXY-4-METHYL-TETRAHYDROPYRANS AS STARTING MATERIALS

Номер: US20220002260A1
Принадлежит:

The present invention relates to a method for preparing 2-substituted 4-methyltetrahydropyrans from 2-substituted 4-hydroxy-4-methyltetrahydropyrans as starting materials. 113-. (canceled)15. The method according to claim 14 , where Ris a straight-chain or branched C-C-alkyl which is unsubstituted or has at least one substituent selected from phenyl and C-C-alkoxy.16. The method according to claim 14 , where Ris methyl claim 14 , ethyl claim 14 , n-propyl claim 14 , isopropyl claim 14 , n-butyl claim 14 , isobutyl claim 14 , n-pentyl claim 14 , n-hexyl or phenyl.17. The method according to claim 16 , wherein Ris isobutyl.18. The method according to claim 14 , wherein the isomeric ratio of cis:trans of compound (I) is in the range from 10:90 to 90:10.19. The method according to claim 18 , wherein the isomeric ratio of cis:trans of compound (I) is in the range from 65:35 to 90:10.20. The method according to claim 14 , wherein the hydrogenation in step b) is carried out in the presence of an acid selected from at least one protic acid claim 14 , at least one Lewis acid claim 14 , at least one acidic ion exchanger claim 14 , at least one oxidic acidic solid claim 14 , at least one acidic molecular element compound and mixtures thereof.21. The method according to claim 14 , wherein the hydrogenation in step b) is carried out in the presence of an acid selected from the group consisting of hydrochloric acid claim 14 , sulfuric acid claim 14 , phosphoric acid claim 14 , nitric acid claim 14 , acetic acid claim 14 , formic acid claim 14 , trifluoromethanesulfonic acid claim 14 , methanesulfonic acid claim 14 , p-toluenesulfonic acid claim 14 , aluminum chloride claim 14 , boron trifluoride claim 14 , zinc chloride claim 14 , phosphorus pentafluoride claim 14 , arsenic trifluoride claim 14 , tin tetrachloride claim 14 , titanium tetrachloride claim 14 , antimony pentafluoride and mixtures thereof.22. The method according to claim 14 , wherein the hydrogenation in step b) is ...

Подробнее
06-01-2022 дата публикации

METHOD FOR PRODUCING TRIARYLORGANOBORATES

Номер: US20220002321A1
Принадлежит:

The invention relates to a process for preparing triaryl organoborates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms. 1. Process for preparing triaryl organoborates of the formula 1/n KRB—R(IV) , where one equivalent of organoboronic ester of the formula B—R(OR)(OR) (I) is initially charged together with 1/n equivalents of salt K nX (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1 , 3 equivalents of a haloaromatic R—Y (III) are added , an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n K RB—R(IV) is separated off with the organic phase and{'sup': '1', 'sub': 1', '22', '3', '22', '3', '22', '5', '7', '7', '13, 'Ris an optionally hydroxyl- and/or alkoxy- and/or acyloxy- and/or halogen-substituted C- to C-alkyl, C- to C-alkenyl, C- to C-alkynyl, C- to C-cycloalkyl or C- to C-aralkyl radical,'}{'sup': 2', '3', '2', '3, 'sub': 1', '22', '3', '7, 'Rand Rare independently an optionally branched C- to C-alkyl radical or an optionally alkyl-substituted C- to C-cycloalkyl radical or Rand Rtogether form a 2-8-membered carbon bridge which is optionally substituted by alkyl and/or interrupted by oxygen atoms,'}{'sup': '4', 'sub': 6', '10', '1', '4', '1', '4, 'Ris a C- to C-aryl radical optionally substituted by at least one radical selected from halogen, C- to C-alkyl, trifluoromethyl, C- to C-alkoxy, trifluoromethoxy, phenyl and phenoxy,'}K is an organocation of valency n and having any substitution, based on nitrogen, phosphorus, oxygen, sulfur and/or iodine, and{'sup': 2', '3, 'L is an auxiliary that forms a complex of sparing solubility in S1 and/or S2 with M salts MY(OR), MY(OR) and MXY, where L is a Lewis-basic compound, especially selected from the group consisting of open chain ...

Подробнее
07-01-2016 дата публикации

AMIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS INSECTICIDE

Номер: US20160002198A1
Принадлежит:

An object of the present invention is to provide a compound represented by Formula (1): 114-. (canceled) The present invention relates to a compound represented by Formula (1):wherein A, A, Aand Aeach represent a carbon atom, a nitrogen atom or an oxidized nitrogen atom;Rand Reach represent a hydrogen atom, an optionally substituted alkyl group or an optionally substituted C1-C4 alkylcarbonyl group;Gand Geach represent an oxygen atom or a sulfur atom;X, which may be identical or different, represents a hydrogen atom, a halogen atom, a C1-C3 alkyl group or a trifluoromethyl group;n is an integer of 0 to 4; andQand Qeach represent an optionally substituted phenyl group, an optionally substituted naphthyl group or an optionally substituted heterocyclic group,an insecticide comprising the compound as the active ingredient, and a process for preparation thereof and use thereof.International Publication WO 2000/55120 and U.S. Pat. No. 6,548,514 describe a compound similar to the compound of the present invention for the use as medicament, but they do not describe on the insecticidal activity of the compound. The compound clearly does not fall within the scope of claims of the present invention.International Publication WO 2000/7980 describes a compound similar to the compound of the present invention for the use as medicament, but it does not describe on the insecticidal activity of the compound. The compound clearly does not fall within the scope of claims of the present invention.US Patent Laid-Open No. 2002-032238 describes a compound similar to the compound of the present invention for the use as medicament, but it does not describe on the insecticidal activity of the compound. The compound clearly does not fall within the scope of claims of the present invention.The object of the present invention is to provide a pesticide having a high insecticidal efficacy. Another object of the present invention is to provide a compound represented by Formula (1), a process for ...

Подробнее
07-01-2016 дата публикации

METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES

Номер: US20160002211A1
Принадлежит: Shionogi & Co., Ltd.

The present invention provides a pyrone derivative and a pyridone derivative, which are novel intermediates for synthesizing an anti-influenza drug, a method of producing the same, and a method of using the same. 118-. (canceled)22. A crystal according to claim 19 , which is characterized by a powder X-ray diffraction spectrum which is substantially consistent with .23. A crystal according to claim 20 , which is characterized by a powder X-ray diffraction spectrum which is substantially consistent with .24. A crystal according to claim 21 , which is characterized by a powder X-ray diffraction spectrum which is substantially consistent with . The present invention relates to a pyrone derivative and a pyridone derivative, which are novel intermediates for synthesizing an anti-influenza drug exhibiting the cap-dependent endonuclease inhibitory activity, a method of producing the same, and a method of using the same.Influenza is an acute respiratory infectious disease caused by infection with an influenza virus. In Japan, there is a report of a few millions of influenza-like patients every winter, and influenza is accompanied with high morbidity and mortality. Influenza is a particularly important disease in a high risk population such as baby and elderly, a complication rate with pneumonia is high in elderly, and death with influenza is occupied with elderly in many cases.As anti-influenza drugs, Symmetrel (trade name: Amantadine) and Flumadine (trade name: Rimantadine) which inhibit the denucleation process of a virus, and Oseltamivir (trade name: Tamiflu) and Zanamivir (trade name: Relenza) which are neuraminidase inhibitors suppressing virus budding and release from a cell are known. However, since problems of appearances of resistant strains and side effects, and worldwide epidemic of a new-type influenza virus having high pathogenicity and mortality are feared, development of an anti-influenza drug having a novel mechanism has been desired.Since a cap-dependent ...

Подробнее
03-01-2019 дата публикации

C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same

Номер: US20190002425A1
Принадлежит:

The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent. 2. The compound represented by the Formula 1 or the pharmaceutically acceptable salts thereof claim 1 , according to claim 1 , wherein{'sub': '2', 'X and Y are each independently —CH— or —O—;'}m is 1 or 2;R1 to R3 are each independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C3-C7 cycloalkyl, hydroxy, C1-C4 alkoxy, —OCF3, —SR5 or aryl (wherein at least one hydrogen of the said C1-C4 alkyl, C2-C4 alkenyl and C3-C7 cycloalkyl may be each independently unsubstituted or substituted with halogen or hydroxy, and hydrogen of the said aryl may be each independently unsubstituted or substituted with at least one substituent selected from the group consisting of halogen, C1-C4 alkyl, hydroxy and C1-C4 alkoxy); and{'sub': '5', 'Ris C1-C4 alkyl.'}3. The compound represented by the Formula 1 or the pharmaceutically acceptable salts thereof claim 1 , according to claim 1 , wherein{'sub': '2', 'X and Y are each independently —CH— or —O—;'}m is 1 or 2;{'sub': '1', 'Ris hydrogen, halogen, C1-C4 alkyl, C3-C7 cycloalkyl or C1-C4 alkoxy (wherein at least one hydrogen of the said C1-C4 alkyl may be each independently unsubstituted or substituted with halogen);'}{'sub': 2', '3, 'Rand Rare each independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C3-C7 cycloalkyl, C1-C4 alkoxy, —OCF3, —SR5 or aryl (wherein at least one hydrogen of the said C1-C4 alkyl, C2-C4 alkenyl and C3-C7 cycloalkyl may be each independently unsubstituted or substituted with halogen, and hydrogen of the said aryl may be each independently unsubstituted or ...

Подробнее